New serum-derived albumin scaffold seeded with adipose-derived stem cells and olfactory ensheathing cells	1
New serum-derived albumin scaffold	1
adipose-derived stem cells and olfactory ensheathing cells	48
adipose-derived stem cells	48
olfactory ensheathing cells	79
spinal cord injured rats Amaia Ferrero-Gutierrez1 *	121
spinal cord	121
rats Amaia Ferrero-Gutierrez1 *	141
rats Amaia Ferrero-Gutierrez1	141
rats	141
Amaia Ferrero-Gutierrez1	147
Yolanda Menendez-Menendez1 *	174
Yolanda Menendez-Menendez1	174
Yolanda	174
Menendez-Menendez1	182
Maria Alvarez-Viejo1	203
Alvaro Meana2	225
Jesus	243
Otero1 1Transplant and Cell Therapy Unit	249
Otero1 1Transplant	249
Cell Therapy Unit	272
Hospital Universitario Central de Asturias , Oviedo , Spain and 2Tissue Engineering Research Unit , Centro Comunitario de Sangre y Tejidos de Asturias , Oviedo , Spain .	291
Hospital Universitario Central de Asturias	291
Oviedo , Spain and 2Tissue Engineering Research Unit	335
Centro Comunitario de Sangre y Tejidos de Asturias	388
Centro Comunitario de Sangre	388
y Tejidos de Asturias	417
Oviedo	440
Spain	448
U714 Ciber Enfermedades Raras -LRB- CIBERER -RRB- .	455
U714 Ciber Enfermedades Raras	455
CIBERER	486
These authors	497
this work	539
Summary .	552
Recent advances	561
spinal cord injury	580
SCI	600
research and cell culture techniques and biomaterials	605
promising new treatments for patients with SCI or other nerve injuries	667
promising new treatments	667
patients with SCI or other nerve injuries	696
patients	696
SCI or other nerve injuries	710
SCI	710
other nerve injuries	717
Biomaterial scaffolds	739
a substrate	766
cells	791
a tissue in a controlled manner	820
a tissue	820
a controlled manner	832
This study	853
axon regeneration and locomotor recovery in rats	887
axon regeneration and locomotor recovery	887
rats	931
spinal cord injury treated with a novel serumderived albumin scaffold seeded with adipose derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB-	941
spinal cord injury	941
a novel serumderived albumin scaffold seeded with adipose derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB-	973
a novel serumderived albumin scaffold	973
adipose derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB-	1023
adipose	1023
stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB-	1039
stem cells -LRB- ADSCs -RRB-	1039
stem cells	1039
ADSCs	1051
olfactory ensheathing cells -LRB- OECs -RRB-	1062
olfactory ensheathing cells	1062
OECs	1091
OECs	1098
promising candidates	1118
the treatment of SCI	1143
the treatment	1143
SCI	1160
ADSCs	1169
the ability to differentiate into neural lineages	1180
neural lineages	1214
In vitro experiments	1231
ADSCs and OECs	1266
the scaffold	1292
specific markers of their cell types	1336
specific markers	1336
their cell types	1356
the scaffold	1390
Rats treated with scaffold plus cells	1404
Rats	1404
scaffold plus cells	1422
scaffold	1422
cells	1436
locomotor skills	1449
several time points	1469
45 days post-injury that were improved over those recorded in control injured , untreated animals	1494
45 days	1494
that	1514
those recorded in control injured	1538
those	1538
control injured	1556
control	1556
Astrocytic scars and tissue regeneration , identified using histological and immunohistochemical techniques ,	1592
Astrocytic scars and tissue regeneration	1592
histological and immunohistochemical techniques	1651
the scaffold	1723
a significant role	1760
glial scar formation and filling of the lesion cavity	1791
glial scar formation and filling	1791
the lesion cavity	1827
cells	1850
the presence of ADSCs and OECs in the scaffold	1857
the presence	1857
ADSCs and OECs in the scaffold	1873
ADSCs and OECs	1873
the scaffold	1891
the appearance of cells	1911
the appearance	1911
cells	1929
markers of neurons and axons	1946
markers	1946
neurons and axons	1957
the injury site	1978
Our findings	1995
the clinical feasibility of an albumin scaffold seeded with ADSCs and OECs as a treatment candidate for use in spinal cord injury repair studies	2017
the clinical feasibility	2017
an albumin scaffold seeded with ADSCs and OECs as a treatment candidate for use in spinal cord injury repair studies	2045
an albumin scaffold	2045
ADSCs and OECs	2077
a treatment candidate for use in spinal cord injury repair studies	2095
a treatment candidate	2095
use in spinal cord injury repair studies	2121
use	2121
spinal cord injury repair studies	2128
Introduction Spinal cord injury -LRB- SCI -RRB-	2164
Introduction Spinal cord injury	2164
Introduction	2164
Spinal cord injury	2177
SCI	2197
a devastating condition that generally produces partial or complete sensory and motor loss below the level of injury	2205
a devastating condition	2205
partial or complete sensory and motor loss	2253
partial or complete sensory	2253
motor loss	2285
the level of injury	2302
the level	2302
injury	2315
SCI	2341
axonal structural and electrophysiological abnormalities	2346
both gray and white matter -LRB- Balentine , 1978 -RRB-	2418
both gray and white matter	2418
Balentine , 1978	2446
Balentine	2446
1978	2457
Trauma	2464
the death of neurons and glial cells as well as axon tract injury	2478
the death of neurons and glial cells	2478
the death	2478
neurons and glial cells	2491
neurons	2491
glial cells	2503
axon tract injury	2526
dead neurons	2551
axons are not spontaneously regenerated	2593
axons	2593
functional disorders	2634
Cadelli et al. , 1992 ; Schwab and Caroni , 2008	2670
Cadelli	2670
et al. , 1992 ; Schwab and Caroni , 2008	2678
et al. , 1992	2678
et al.	2678
1992	2686
Schwab and Caroni , 2008	2692
Schwab and Caroni	2692
2008	2711
The lesion site produced by SCI	2718
The lesion site	2718
SCI	2746
many obstacles	2756
tissue and cell regeneration	2785
Events subsequent to SCI	2815
Events	2815
SCI	2836
the formation of a cystic cavity	2848
the formation	2848
a cystic cavity	2865
the injury site , which becomes surrounded by a glial and fibrous scar , composed of mainly reactive astrocytes , thus generating a physical barrier to spontaneous regeneration -LRB- Fawcett and Asher , 1999 ; Brazda and Müller , 2009 -RRB-	2884
the injury site	2884
a glial and fibrous scar , composed of mainly reactive astrocytes	2929
a glial and fibrous scar	2929
mainly reactive astrocytes	2967
a physical barrier	3011
spontaneous regeneration -LRB- Fawcett and Asher , 1999 ; Brazda and Müller , 2009 -RRB-	3033
spontaneous regeneration	3033
Fawcett and Asher , 1999 ; Brazda and Müller , 2009	3059
Fawcett and Asher	3059
1999 ; Brazda and Müller	3078
1999	3078
Brazda and Müller	3084
2009	3104
addition	3114
the demyelination that occurs after SCI	3124
the demyelination	3124
SCI	3160
several inhibitory molecules and signals that contribute to this lack of regeneration -LRB- McGee and Strittmatter , 2003 ; Busch and Silver , 2007 -RRB-	3173
several inhibitory molecules and signals	3173
this lack of regeneration -LRB- McGee and Strittmatter , 2003 ; Busch and Silver , 2007 -RRB-	3233
this lack	3233
regeneration -LRB- McGee and Strittmatter , 2003 ; Busch and Silver , 2007 -RRB-	3246
regeneration	3246
McGee and Strittmatter , 2003 ; Busch and Silver , 2007	3260
McGee and Strittmatter	3260
2003 ; Busch and Silver	3284
2003	3284
Busch and Silver	3290
2007	3308
Preliminary empirical experiments designed to either maintain or recover neuronal functions	3315
Preliminary empirical experiments	3315
neuronal functions	3388
injured axons	3436
lost neurons	3464
cell transplantation -LRB- Li et al. , 2004 ; Wang et al. , 2006 -RRB-	3480
cell transplantation	3480
Li	3502
et al. , 2004 ; Wang et al. , 2006	3505
et al.	3505
2004 ; Wang et al.	3513
2004	3513
Wang et al.	3519
Wang	3519
et al.	3524
2006	3532
central nervous system lesions	3539
glial cells , such as olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Raisman , 2001 ; Barnett and Riddell , 2004 -RRB-	3574
glial cells	3574
olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Raisman , 2001 ; Barnett and Riddell , 2004 -RRB-	3595
olfactory ensheathing cells -LRB- OECs -RRB-	3595
olfactory ensheathing cells	3595
OECs	3624
Raisman , 2001 ; Barnett and Riddell , 2004	3631
Raisman	3631
2001 ; Barnett and Riddell	3640
2001	3640
Barnett and Riddell	3646
2004	3667
OECs	3674
astrocytic scars	3721
axonal regrowth	3761
neural regeneration and functional reconstruction -LRB- Raisman , 1985 -RRB-	3788
neural regeneration and functional reconstruction	3788
regeneration	3795
Raisman , 1985	3839
Raisman	3839
1985	3848
In vitro and in vivo studies	3855
vivo	3871
the injection of OECs at the injury site	3900
the injection	3900
OECs at the injury site	3917
OECs	3917
the injury site	3925
a favorable environment	3949
the regeneration and remyelination of central cord axons	3977
the regeneration and remyelination	3977
central cord axons	4015
functional recovery	4056
animal models of SCI -LRB- Groves et al. , 1993 ; Ramon-Cueto et al. , 1998 ; Radtke et al. , 2009 -RRB-	4079
animal models	4079
SCI -LRB- Groves et al. , 1993 ; Ramon-Cueto et al. , 1998 ; Radtke et al. , 2009 -RRB-	4096
SCI	4096
Groves et al. , 1993 ; Ramon-Cueto et al. , 1998 ; Radtke et al. , 2009	4101
Groves	4101
et al. , 1993 ; Ramon-Cueto et al. , 1998 ; Radtke et al. , 2009	4108
et al. , 1993	4108
et al.	4108
1993	4116
Ramon-Cueto et al. , 1998	4122
Ramon-Cueto	4122
et al. , 1998	4134
et al.	4134
1998	4142
Radtke et al. , 2009	4148
Radtke	4148
et al. , 2009	4155
et al.	4155
2009	4163
OEC transplantation	4170
the availability of functional cells	4212
the availability	4212
functional cells	4232
A promising new cell strategy	4250
the use of adult mesenchymal stem cells -LRB- MSC -RRB-	4292
the use	4292
adult mesenchymal stem cells -LRB- MSC -RRB-	4303
adult mesenchymal stem cells	4303
MSC	4333
Adipose-derived stem cells -LRB- ADSCs -RRB-	4339
Adipose-derived stem cells	4339
ADSCs	4367
a neuronal phenotype	4408
the possible use of these cells to treat neurological disorders	4462
the possible use	4462
these cells	4482
neurological disorders	4503
the attention of researchers -LRB- Kang et al. , 2003 -RRB-	4540
the attention	4540
researchers -LRB- Kang et al. , 2003 -RRB-	4557
researchers	4557
Kang	4570
et al. , 2003	4575
et al.	4575
2003	4583
the injection of OECs directly into the site of SCI	4599
the injection	4599
OECs directly into the site of SCI	4616
OECs	4616
the site of SCI	4635
the site	4635
SCI	4647
limited use -LRB- Resnick et al. , 2003 ; Collazos-Castro et al. , 2005 -RRB-	4666
limited use	4666
Resnick	4679
et al. , 2003 ; Collazos-Castro et al. , 2005	4687
et al.	4687
2003 ; Collazos-Castro et al.	4695
2003	4695
Collazos-Castro et al.	4701
Collazos-Castro	4701
et al.	4717
2005	4725
some of the neurotrophic factors	4732
some	4732
the neurotrophic factors	4740
OECs have been successfully used to induce MSC differentiation into neurons and glial cells in vitro -LRB- Jin et al. , 2003 ; Tatard et al. , 2007 -RRB-	4777
OECs have been successfully used to induce MSC differentiation into neurons and glial cells in vitro	4777
OECs	4777
MSC differentiation	4820
neurons and glial cells	4845
neurons	4845
glial cells	4857
Jin	4879
et al. , 2003 ; Tatard et al. , 2007	4883
et al.	4883
2003 ; Tatard et al.	4891
2003	4891
Tatard et al.	4897
Tatard	4897
et al.	4904
2007	4912
other authors -LRB- Zhang et al. , 2009 ; Arboleda et al. , 2011 -RRB-	4928
other authors	4928
Zhang	4943
et al. , 2009 ; Arboleda et al. , 2011	4949
et al.	4949
2009 ; Arboleda et al.	4957
2009	4957
Arboleda et al.	4963
Arboleda	4963
et al.	4972
2011	4980
the functional improvement in animals with SCI transplanted with MSCs	4996
the functional improvement	4996
animals with SCI transplanted with MSCs	5026
animals	5026
SCI transplanted with MSCs	5039
SCI	5039
MSCs	5061
the release of trophic factors via a paracrine effect	5083
the release	5083
trophic factors via a paracrine effect	5098
trophic factors	5098
a paracrine effect	5118
Biodegradable polymer scaffolds	5138
a structural support	5184
the injury site and guide axon regeneration -LRB- Olson et al. , 2009 ; Straley et al. , 2010 -RRB-	5215
the injury site and guide axon regeneration	5215
Olson	5260
et al. , 2009 ; Straley et al. , 2010	5266
et al.	5266
2009 ; Straley et al.	5274
2009	5274
Straley et al.	5280
Straley	5280
et al.	5288
2010	5296
The scaffold used in the present study	5303
The scaffold	5303
the present study	5324
a biodegradable cross-linked plasma-based matrix that serves as a three-dimensional substrate	5346
a biodegradable cross-linked plasma-based matrix	5346
a three-dimensional substrate	5410
An essential benefit of this new scaffold	5441
An essential benefit	5441
this new scaffold	5465
it	5491
the patient 's own blood	5511
the patient 's	5511
an autologous scaffold	5554
the risks of foreign body reaction or infection -LRB- Gallego et al. , 2010 -RRB-	5587
the risks	5587
foreign body reaction or infection -LRB- Gallego et al. , 2010 -RRB-	5600
foreign body reaction or infection	5600
Gallego	5636
et al. , 2010	5644
et al.	5644
2010	5652
effect	5662
this new scaffold	5670
many tissue-engineering applications	5699
previous experimental studies	5744
we	5774
its successful use	5787
bone defects -LRB- Gallego et al. , 2009 , 2010 -RRB-	5816
bone defects	5816
Gallego	5830
et al. , 2009 , 2010	5838
et al.	5838
2009	5846
2010	5852
The present study	5859
the effect of a combination of adipose derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB- seeded in a novel serum-derived albumin scaffold on SCI	5900
the effect	5900
a combination of adipose derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB- seeded in a novel serum-derived albumin scaffold on SCI	5914
a combination	5914
adipose derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB- seeded in a novel serum-derived albumin scaffold on SCI	5931
adipose	5931
stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB- seeded in a novel serum-derived albumin scaffold on SCI	5947
stem cells -LRB- ADSCs -RRB-	5947
stem cells	5947
ADSCs	5959
olfactory ensheathing cells -LRB- OECs -RRB- seeded in a novel serum-derived albumin scaffold on SCI	5970
olfactory ensheathing cells -LRB- OECs -RRB-	5970
olfactory ensheathing cells	5970
OECs	5999
a novel serum-derived albumin scaffold on SCI	6015
a novel serum-derived albumin scaffold	6015
SCI	6057
Materials and methods Scaffold preparation The scaffold	6063
Materials	6063
methods Scaffold preparation The scaffold	6077
methods	6077
Scaffold preparation	6085
The scaffold	6106
as previously described -LRB- Meana et al. , 2008 ; Gallego et al. , 2010 -RRB- according to patent WO2008/119855	6134
as previously described -LRB- Meana et al. , 2008 ; Gallego et al. , 2010 -RRB-	6134
as previously described	6134
as previously	6134
Meana	6159
et al. , 2008 ; Gallego et al. , 2010	6165
et al.	6165
2008 ; Gallego et al.	6173
2008	6173
Gallego et al.	6179
Gallego	6179
et al.	6187
2010	6195
WO2008/119855	6221
brief	6239
10 ml of human venous blood	6246
10 ml	6246
human venous blood	6255
a blood bank	6292
30 min	6318
37 °C	6328
the blood	6340
15 min at 2000 g	6370
15 min	6370
2000 g	6380
the resultant serum -LRB- 5 ml -RRB-	6391
the resultant serum	6391
5 ml	6412
0.5 ml	6439
25 % glutaraldehyde -LRB- Merck , Darmstadt , Germany -RRB-	6446
25 % glutaraldehyde	6446
Merck	6466
Darmstadt	6473
Germany	6484
a 5 ml disposable syringe	6512
5 ml	6514
the serum / glutaraldehyde solution at room temperature for 30 min	6553
the serum / glutaraldehyde solution at room temperature	6553
the serum	6553
glutaraldehyde solution at room temperature	6564
glutaraldehyde solution	6564
room temperature	6591
30 min	6612
solidification	6625
it	6641
-70 °C overnight	6667
-70 °C	6667
the syringe	6689
the frozen solution	6718
48 h	6758
a graded ethanol series -LRB- 100-90-80 % -RRB- by immersing for 1 h in each dilution	6781
a	6781
ethanol series -LRB- 100-90-80 % -RRB-	6790
ethanol series	6790
100-90-80 %	6806
1 h in each dilution	6835
1 h	6835
each dilution	6842
The tube-shaped scaffold obtained	6857
The tube-shaped scaffold	6857
3 mm-diameter , 1-2 mm-thick sections	6909
3 mm-diameter	6909
1-2 mm-thick sections	6924
70 % ethanol	6964
8 h.	6980
these small tubes of scaffold	6994
these small tubes	6994
scaffold	7015
Dulbecco 's	7044
Eagle 's medium -LRB- DMEM ; Gibco Invitrogen , Paisley , United Kingdom -RRB-	7064
Eagle 's medium	7064
Eagle 's	7064
DMEM ; Gibco Invitrogen , Paisley , United Kingdom	7080
DMEM	7080
Gibco Invitrogen , Paisley , United Kingdom	7086
cell seeding	7137
excess fluid	7151
the scaffolds	7180
a 24 - well culture plate -LRB- Nunc , Darmstadt , Germany -RRB- as one scaffold per well	7209
a 24	7209
culture plate -LRB- Nunc , Darmstadt , Germany -RRB-	7220
culture plate	7220
Nunc	7235
Darmstadt	7241
Germany	7252
one scaffold per well	7264
one scaffold	7264
Adipose-derived stem cell -LRB- ADSCs -RRB- cultures 1-2 g of abdominal mesenteric adipose tissue	7287
Adipose-derived stem cell -LRB- ADSCs -RRB- cultures 1-2 g	7287
Adipose-derived stem cell -LRB- ADSCs -RRB- cultures	7287
ADSCs	7314
1-2 g	7330
abdominal mesenteric adipose tissue	7339
Wistar rats	7393
anesthesia induced by isoflurane inhalation -LRB- Esteve laboratories , Milan , Italy -RRB- , washed three times in phosphate-buffered saline -LRB- PBS ; PAA Laboratories GmbH , Cölbe , Germany -RRB- , chopped and placed in a test tube	7411
anesthesia	7411
isoflurane inhalation -LRB- Esteve laboratories , Milan , Italy -RRB-	7433
isoflurane inhalation	7433
Esteve laboratories	7456
Milan	7477
Italy	7484
three times in phosphate-buffered saline -LRB- PBS ; PAA Laboratories GmbH , Cölbe , Germany -RRB- , chopped	7499
three times	7499
phosphate-buffered saline	7514
PBS	7541
PAA Laboratories GmbH , Cölbe , Germany	7546
PAA Laboratories GmbH	7546
Cölbe	7569
Germany	7576
a test tube	7608
0.1 % collagenase I -LRB- Sigma-Aldrich , Madrid , Spain -RRB-	7634
0.1 % collagenase I	7634
Sigma-Aldrich	7654
Madrid	7669
Spain	7677
DMEM -LRB- Gibco Invitrogen -RRB-	7687
DMEM	7687
Gibco Invitrogen	7693
the suspension	7712
1 h at 37 °C	7755
1 h	7755
37 °C	7762
Digestion	7768
fetal bovine serum -LRB- FBS ; Gibco Invitrogen -RRB-	7800
fetal bovine serum	7800
FBS ; Gibco Invitrogen	7820
FBS	7820
Gibco Invitrogen	7825
a 0.40 μm cell strainer -LRB- BD Bioscience , Madrid , Spain -RRB- and centrifuging at 500 g for 10 min	7868
a 0.40 μm cell strainer -LRB- BD Bioscience , Madrid , Spain -RRB-	7868
a 0.40 μm cell strainer	7868
BD Bioscience	7893
Madrid	7908
Spain	7916
centrifuging at 500 g for 10 min	7927
centrifuging	7927
500 g for 10 min	7943
500 g	7943
10 min	7953
the cells	7961
25 cm2 polystyrene flasks -LRB- Cultek , Madrid , Spain -RRB-	7986
25 cm2 polystyrene flasks	7986
Cultek	8013
Madrid	8021
Spain	8029
an ADSCs culture medium consisting of low-dose sugar DMEM -LRB- Gibco Invitrogen -RRB- supplemented with 10 % FBS , 100 U/ml penicillin -LRB- Gibco Invitrogen -RRB- , and 100 μg/ml streptomycin -LRB- Gibco Invitrogen -RRB-	8039
an ADSCs culture medium	8039
low-dose sugar DMEM -LRB- Gibco Invitrogen -RRB- supplemented with 10 % FBS , 100 U/ml penicillin -LRB- Gibco Invitrogen -RRB- , and 100 μg/ml streptomycin -LRB- Gibco Invitrogen -RRB-	8077
low-dose sugar DMEM	8077
Gibco Invitrogen	8098
10 % FBS , 100 U/ml penicillin -LRB- Gibco Invitrogen -RRB- , and 100 μg/ml streptomycin -LRB- Gibco Invitrogen -RRB-	8134
10 % FBS	8134
100 U/ml penicillin -LRB- Gibco Invitrogen -RRB-	8144
100 U/ml penicillin	8144
Gibco Invitrogen	8165
100 μg/ml streptomycin -LRB- Gibco Invitrogen -RRB-	8188
100 μg/ml streptomycin	8188
Gibco Invitrogen	8212
Cells	8231
a controlled atmosphere -LRB- 37 °C , 5 % CO2 -RRB-	8254
a controlled atmosphere	8254
37 °C , 5 % CO2	8279
37 °C	8279
5 % CO2	8285
48 h	8296
the medium	8302
unattached cells	8336
the medium	8374
every 2-3 days	8401
the 14th day	8424
the cells	8454
trypsin -LRB- 0.25 % w/v ; Gibco Invitrogen -RRB-	8483
trypsin	8483
0.25 % w/v ; Gibco Invitrogen	8492
0.25 % w/v	8492
Gibco Invitrogen	8504
four times	8535
their use	8553
Olfactory ensheathing cells -LRB- OECs -RRB- cultures and purification Primary olfactory bulb -LRB- OB -RRB- cells from adult female Wistar rats -LRB- three months old ; Harlan Laboratories , Germany -RRB-	8564
Olfactory ensheathing cells -LRB- OECs -RRB- cultures	8564
Olfactory ensheathing cells	8564
OECs	8593
cultures	8599
purification Primary olfactory bulb -LRB- OB -RRB- cells from adult female Wistar rats -LRB- three months old ; Harlan Laboratories , Germany -RRB-	8612
purification	8612
Primary olfactory bulb -LRB- OB -RRB- cells from adult female Wistar rats -LRB- three months old ; Harlan Laboratories , Germany -RRB-	8625
Primary olfactory bulb -LRB- OB -RRB- cells	8625
OB	8649
adult female Wistar rats -LRB- three months old ; Harlan Laboratories , Germany -RRB-	8664
adult female Wistar rats	8664
three months old ; Harlan Laboratories , Germany	8690
three months old	8690
Harlan Laboratories , Germany	8708
Harlan Laboratories	8708
Germany	8729
detail -LRB- Gudiño-Cabrera and Nieto-Sampedro , 1996 -RRB-	8778
detail	8778
Gudiño-Cabrera and Nieto-Sampedro , 1996	8786
Gudiño-Cabrera and Nieto-Sampedro	8786
1996	8821
The method used to purify OECs from these primary OB cultures	8828
The method	8828
OECs	8854
these primary OB cultures	8864
the original protocol -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 -RRB-	8908
the original protocol	8908
Ramon-Cueto and Nieto-Sampedro , 1994	8931
Ramon-Cueto and Nieto-Sampedro	8931
1994	8963
14 days	8976
OECs	8999
other cell types in primary cultures	9024
other cell types	9024
primary cultures	9044
immunoaffinity using an antibody against the p-75 nerve growth factor receptor -LRB- p-75 NGFR ; Chemicon , Millipore , Madrid , Spain -RRB- -LRB- 1:1000 -RRB-	9064
immunoaffinity	9064
an antibody against the p-75 nerve growth factor receptor -LRB- p-75 NGFR ; Chemicon , Millipore , Madrid , Spain -RRB- -LRB- 1:1000 -RRB-	9085
an antibody	9085
the p-75 nerve growth factor receptor -LRB- p-75 NGFR ; Chemicon , Millipore , Madrid , Spain -RRB- -LRB- 1:1000 -RRB-	9105
the p-75 nerve growth factor receptor -LRB- p-75 NGFR ; Chemicon , Millipore , Madrid , Spain -RRB-	9105
the p-75 nerve growth factor receptor	9105
p-75 NGFR ; Chemicon , Millipore , Madrid , Spain	9144
p-75 NGFR	9144
Chemicon , Millipore , Madrid , Spain	9155
1:1000	9192
Cells from primary cultures	9201
Cells	9201
primary cultures	9212
0.25 % trypsin	9248
200 g ; 10 min	9276
200 g	9276
10 min	9283
the p-75 NGFR antibody for 45 min	9311
the p-75 NGFR antibody	9311
45 min	9338
room temperature	9348
the cells	9372
PBS/BSA/EDTA	9403
monoclonal IgG attached to Dynabeads M-450 -LRB- DBM-450 ; magnetic beads , coated with goat anti-mouse IgG ; Miltenyi Biotec , Madrid , Spain -RRB- for 30 min at 4 °C	9435
monoclonal IgG	9435
Dynabeads M-450 -LRB- DBM-450 ; magnetic beads , coated with goat anti-mouse IgG ; Miltenyi Biotec , Madrid , Spain -RRB- for 30 min at 4 °C	9462
Dynabeads M-450 -LRB- DBM-450 ; magnetic beads , coated with goat anti-mouse IgG ; Miltenyi Biotec , Madrid , Spain -RRB-	9462
Dynabeads M-450	9462
DBM-450 ; magnetic beads , coated with goat anti-mouse IgG ; Miltenyi Biotec , Madrid , Spain	9479
DBM-450	9479
magnetic beads , coated with goat anti-mouse IgG	9488
magnetic beads	9488
goat anti-mouse IgG	9516
Miltenyi Biotec , Madrid , Spain	9537
Miltenyi Biotec	9537
Madrid , Spain	9554
30 min at 4 °C	9573
30 min	9573
4 °C	9583
The cells	9588
the magnetic beads	9627
the cells that did not express p75-NGFR with the help of a potent permanent magnet -LRB- 69 -RRB- to retain the magnetic bead-OEC complexes	9665
the cells	9665
p75-NGFR	9696
the help of a potent permanent magnet -LRB- 69 -RRB-	9710
the help	9710
a potent permanent magnet -LRB- 69 -RRB-	9722
a potent permanent magnet	9722
69	9749
the magnetic bead-OEC complexes	9763
These complexes	9796
three times	9824
PBS/BSA/EDTA	9839
the OECs	9856
a poly-L-lysine-treated -LRB- Sigma-Aldrich ; average molecular weight , 30,000 ; 50 mg/ml -RRB-	9877
a poly-L-lysine-treated	9877
Sigma-Aldrich ; average molecular weight	9902
Sigma-Aldrich	9902
average molecular weight	9917
30,000 ; 50 mg/ml	9943
30,000	9943
50 mg/ml	9951
25 cm2 flask followed by incubation for 48 h in an OEC culture medium -LRB- 1:1 mixture of DMEM and Ham 's F-12 medium -LRB- Lonza , Barcelona , Spain -RRB- supplemented with 10 % FBS , 100 U/ml penicillin , and 100 μg/ml streptomycin -RRB- at 37 °C in a 5 % CO2 atmosphere	9961
25 cm2 flask followed by incubation for 48 h in an OEC culture medium -LRB- 1:1 mixture of DMEM and Ham 's F-12 medium -LRB- Lonza , Barcelona , Spain -RRB- supplemented with 10 % FBS , 100 U/ml penicillin , and 100 μg/ml streptomycin -RRB-	9961
25 cm2 flask followed by incubation for 48 h in an OEC culture medium	9961
25 cm2 flask	9961
incubation for 48 h in an OEC culture medium	9986
incubation	9986
48 h in an OEC culture medium	10001
48 h	10001
an OEC culture medium	10009
1:1 mixture of DMEM and Ham 's F-12 medium -LRB- Lonza , Barcelona , Spain -RRB- supplemented with 10 % FBS , 100 U/ml penicillin , and 100 μg/ml streptomycin	10032
1:1 mixture	10032
DMEM and Ham 's F-12 medium -LRB- Lonza , Barcelona , Spain -RRB-	10047
DMEM	10047
Ham 's F-12 medium -LRB- Lonza , Barcelona , Spain -RRB-	10056
Ham 's F-12 medium	10056
Ham 's	10056
Lonza	10075
Barcelona	10082
Spain	10093
10 % FBS , 100 U/ml penicillin , and 100 μg/ml streptomycin	10118
10 % FBS	10118
100 U/ml penicillin	10127
100 μg/ml streptomycin	10152
37 °C in a 5 % CO2 atmosphere	10179
37 °C	10179
a 5 % CO2 atmosphere	10187
Cell seeding Confluent cultures of ADSCs -LRB- fourth passage -RRB- and OECs	10208
Cell seeding Confluent cultures	10208
ADSCs -LRB- fourth passage -RRB- and OECs	10243
ADSCs -LRB- fourth passage -RRB-	10243
ADSCs	10243
fourth passage	10250
OECs	10270
a Neubauer hemocytometer	10307
The cells released	10333
The cells	10333
DMEM	10370
10 % FBS	10386
the DMEM	10400
the ADSCs and OECs	10427
scaffold culture medium -LRB- DMEM containing 10 % FBS , 100 U/ml penicillin and 100 μg/ml streptomycin plus 25 ng/ml NT-3 -LRB- Sigma -RRB- and 100 ng/ml NGF -LRB- Sigma - Aldrich -RRB- -RRB-	10461
scaffold culture medium	10461
DMEM containing 10 % FBS , 100 U/ml penicillin and 100 μg/ml streptomycin plus 25 ng/ml NT-3 -LRB- Sigma -RRB- and 100 ng/ml NGF -LRB- Sigma - Aldrich -RRB-	10486
DMEM containing 10 % FBS , 100 U/ml penicillin	10486
DMEM	10486
10 % FBS , 100 U/ml penicillin	10502
10 % FBS	10502
100 U/ml penicillin	10511
100 μg/ml streptomycin plus 25 ng/ml NT-3 -LRB- Sigma -RRB- and 100 ng/ml NGF -LRB- Sigma - Aldrich -RRB-	10535
100 μg/ml streptomycin	10535
25 ng/ml NT-3 -LRB- Sigma -RRB- and 100 ng/ml NGF -LRB- Sigma - Aldrich -RRB-	10563
25 ng/ml NT-3	10563
Sigma	10578
100 ng/ml NGF	10589
Sigma - Aldrich	10604
Sigma	10604
Aldrich	10611
1x106 ADSCs -LRB- 0.5 ml -RRB- and 5x105 OECs -LRB- 0.5 ml -RRB-	10628
1x106 ADSCs -LRB- 0.5 ml -RRB-	10628
1x106 ADSCs	10628
0.5 ml	10641
5x105 OECs -LRB- 0.5 ml -RRB-	10653
5x105 OECs	10653
0.5 ml	10665
the scaffolds in the wells	10690
the scaffolds	10690
the wells	10707
The scaffolds	10718
48 h	10760
the cells	10774
The culture medium	10795
week	10840
The cells	10846
7 days at 37 °C in a humidified atmosphere of 5 % CO2	10876
7 days	10876
37 °C in a humidified atmosphere of 5 % CO2	10886
37 °C	10886
a humidified atmosphere of 5 % CO2	10894
a humidified atmosphere	10894
5 % CO2	10921
In vitro experiments The following in vitro study groups	10929
In vitro experiments	10929
The following	10950
study groups	10973
Scaffold control -LRB- n = 5 -RRB- : Scaffold alone	11004
Scaffold control	11004
n	11022
5	11026
Scaffold alone	11030
Scaffold + ADSCs + OECs -LRB- n = 5 -RRB- : ADSCs and OECs co-cultured in the scaffold .	11046
Scaffold + ADSCs + OECs -LRB- n = 5 -RRB-	11046
Scaffold + ADSCs + OECs	11046
Scaffold + ADSCs	11046
OECs	11065
n	11071
5	11075
ADSCs and OECs co-cultured in the scaffold	11079
ADSCs and OECs	11079
the scaffold	11109
electron microscopy -LRB- SEM -RRB-	11132
electron microscopy	11132
SEM	11153
The structural features of the scaffold and cells in the scaffold -LRB- ADSCs and OECs -RRB-	11158
The structural features of the scaffold and cells in the scaffold	11158
The structural features	11158
the scaffold and cells in the scaffold	11185
the scaffold and cells	11185
the scaffold	11211
ADSCs and OECs	11225
ADSCs	11225
OECs	11235
scanning electron microscopy	11258
The scaffolds	11288
2 % phosphate-buffered glutaraldehyde 0.1 M -LRB- Panreac , Barcelona , Spain -RRB-	11316
2 % phosphate-buffered glutaraldehyde 0.1 M	11316
2 % phosphate-buffered glutaraldehyde	11316
Panreac	11360
Barcelona	11369
Spain	11380
12 h	11391
The fixed samples	11397
a graded series of acetone -LRB- 30-50-70 - 90-100 % ; Merck , Darmstadt , Germany -RRB-	11434
a	11434
series of acetone -LRB- 30-50-70 - 90-100 % ; Merck , Darmstadt , Germany -RRB-	11443
series	11443
acetone -LRB- 30-50-70 - 90-100 % ; Merck , Darmstadt , Germany -RRB-	11453
acetone	11453
30-50-70	11462
90-100 % ; Merck , Darmstadt , Germany	11472
90-100 %	11472
Merck , Darmstadt , Germany	11481
critical point	11534
CO2 -LRB- Baltec CDP 030 critical point dryer -RRB-	11555
CO2	11555
Baltec CDP 030 critical point dryer	11560
Baltec CDP	11560
030 critical point dryer	11571
These samples	11598
gold	11637
SEM -LRB- JEOL JSM 6100 , Tokyo , Japan -RRB-	11661
SEM	11661
JEOL JSM 6100 , Tokyo , Japan	11666
JEOL JSM 6100	11666
Tokyo , Japan	11681
Assessment of nuclear morphology The scaffolds	11696
Assessment	11696
nuclear morphology The scaffolds	11710
nuclear morphology	11710
The scaffolds	11729
4 % paraformaldehyde -LRB- Panreac -RRB-	11767
4 % paraformaldehyde	11767
Panreac	11788
0.1 M PBS at 4 °C	11800
0.1 M PBS	11800
4 °C	11813
PBS	11841
the scaffolds	11846
isopentane -LRB- Merck -RRB- and embedded in OCT medium -LRB- Tissue-Tek , Zoeterwoude , Netherlands -RRB- and sections 5 - to 10 μm-thick cut on a cryostat -LRB- model Jung friocut 2800E , Leica , Heerbrugg , Switzerland -RRB-	11875
isopentane -LRB- Merck -RRB-	11875
isopentane	11875
Merck	11887
embedded in OCT medium -LRB- Tissue-Tek , Zoeterwoude , Netherlands -RRB-	11898
embedded in OCT medium	11898
OCT	11910
Tissue-Tek	11922
Zoeterwoude	11934
Netherlands	11947
sections 5 - to 10 μm-thick cut on a cryostat -LRB- model Jung friocut 2800E , Leica , Heerbrugg , Switzerland -RRB-	11964
sections	11964
10 μm-thick cut on a cryostat	11979
10 μm-thick cut	11979
a cryostat	11998
model Jung friocut 2800E , Leica , Heerbrugg , Switzerland	12010
model Jung friocut 2800E	12010
Leica	12036
Heerbrugg	12043
Switzerland	12054
The sections	12068
PBS	12096
the nuclear fluorescent	12127
DAPI -LRB- 1.5 μg/ml -RRB- -LRB- Vectashield mounting medium with DAPI ; Vector Laboratories , Peterborough , United Kingdom -RRB-	12155
DAPI -LRB- 1.5 μg/ml -RRB-	12155
DAPI	12155
1.5 μg/ml	12161
Vectashield mounting medium with DAPI ; Vector Laboratories , Peterborough , United Kingdom	12173
Vectashield mounting medium	12173
DAPI ; Vector Laboratories , Peterborough , United Kingdom	12206
DAPI	12206
Vector Laboratories , Peterborough , United Kingdom	12212
Vector Laboratories	12212
Peterborough , United Kingdom	12233
coverslips	12280
Observations and photographs	12292
an Olympus BX-41 fluorescence microscope coupled to a digital camera -LRB- model DP71 ; Olympus , Barcelona , Spain -RRB- and the results analyzed using the equipment 's image analysis software	12343
an Olympus BX-41 fluorescence microscope	12343
a digital camera -LRB- model DP71 ; Olympus , Barcelona , Spain -RRB- and the results analyzed using the equipment 's image analysis software	12395
a digital camera -LRB- model DP71 ; Olympus , Barcelona , Spain -RRB-	12395
a digital camera	12395
model DP71 ; Olympus , Barcelona , Spain	12413
model DP71	12413
Olympus , Barcelona , Spain	12425
the results analyzed using the equipment 's image analysis software	12456
the results	12456
the equipment 's image analysis software	12483
the equipment 's	12483
Immunohistochemical analysis The scaffolds	12524
Immunohistochemical analysis	12524
The scaffolds	12553
4 % paraformaldehyde in 0.1 M PBS at 4 °C	12591
4 % paraformaldehyde	12591
0.1 M PBS at 4 °C	12614
0.1 M PBS	12614
4 °C	12627
isopentane	12642
OCT medium	12669
sections	12685
10 μm-thick cut on a cryostat	12700
10 μm-thick cut	12700
a cryostat	12719
immunohistochemistry	12735
the sections	12757
glass slides , placed in PBS	12786
glass slides	12786
PBS	12810
endogenous peroxidase	12818
30 min	12854
1 % H2O2	12866
Possible background staining	12875
sections	12930
at least 30 min in 5 % BSA -LRB- Merck -RRB-	12943
at least 30 min	12943
5 % BSA -LRB- Merck -RRB-	12962
5 % BSA	12962
Merck	12970
PBS	12980
Sections	12985
mouse anti-vimentin monoclonal antibody -LRB- Dako , Barcelona , Spain -RRB- -LRB- 1:100 -RRB-	13019
mouse anti-vimentin monoclonal antibody -LRB- Dako , Barcelona , Spain -RRB-	13019
mouse anti-vimentin monoclonal antibody	13019
Dako	13060
Barcelona	13066
Spain	13077
1:100	13085
30 min at room temperature in a humid chamber or with mouse anti-p75 NGFR monoclonal antibody -LRB- Millipore -RRB- -LRB- 1:200 -RRB-	13096
30 min	13096
room temperature in a humid chamber	13106
room temperature	13106
a humid chamber	13126
mouse anti-p75 NGFR	13150
monoclonal antibody -LRB- Millipore -RRB- -LRB- 1:200 -RRB-	13170
monoclonal antibody -LRB- Millipore -RRB-	13170
monoclonal antibody	13170
Millipore	13191
1:200	13203
18 h at 4 °C in a humid chamber	13214
18 h	13214
4 °C in a humid chamber	13222
4 °C	13222
a humid chamber	13229
further rinsing in PBS	13252
further rinsing	13252
PBS	13271
the sections	13276
the secondary antibody conjugated to peroxidase -LRB- Dako -RRB- for 30 min at room temperature in a humid chamber	13321
the secondary antibody	13321
peroxidase -LRB- Dako -RRB- for 30 min	13358
peroxidase -LRB- Dako -RRB-	13358
peroxidase	13358
Dako	13370
30 min	13380
room temperature in a humid chamber	13390
room temperature	13390
a humid chamber	13410
The complexes antibody-vimentin and antibody-p-75 NGFR	13427
The complexes antibody-vimentin	13427
antibody-p-75 NGFR	13463
the REAL EnVision Detection system kit -LRB- Dako -RRB-	13512
the REAL EnVision Detection system kit	13512
Dako	13552
This kit	13559
a 3 ' -3 ' - diaminobenzidine -LRB- DAB -RRB-	13573
a 3 ' -3	13573
a 3	13573
-3	13577
diaminobenzidine -LRB- DAB -RRB-	13582
diaminobenzidine	13582
DAB	13600
chromogen	13610
vimentin and p75-NGFR-positive cells brown	13630
sections	13682
a hydrophobic medium -LRB- Entellan ; Merck -RRB-	13707
a hydrophobic medium	13707
Entellan ; Merck	13729
Entellan	13729
Merck	13739
Other sections	13747
hematoxylin and eosin -LRB- H&E -RRB- for microscopy examination	13780
hematoxylin and eosin -LRB- H&E -RRB-	13780
hematoxylin and eosin	13780
H&E	13803
microscopy examination	13812
Observations and photographs	13836
an Olympus BX-41 microscope	13887
a digital camera -LRB- Olympus -RRB- and the results analyzed using the equipment 's image analysis software	13926
a digital camera -LRB- Olympus -RRB-	13926
a digital camera	13926
Olympus	13944
the results analyzed using the equipment 's image analysis software	13957
the results	13957
the equipment 's image analysis software	13984
the equipment 's	13984
In vivo experiments Spinal cord injury model The SCI model used	14025
In vivo experiments	14025
Spinal cord injury model The SCI model	14045
Spinal cord injury model	14045
The SCI model	14070
Demjen	14111
et al. -LRB- 2004 -RRB- in which injury is produced by severing the leaving a small hinge uncut -LRB- the cord is thus around 80 % transected -RRB-	14118
et al.	14118
2004	14126
injury	14141
the	14172
a small hinge uncut -LRB- the cord is thus around 80 % transected -RRB-	14184
a small hinge uncut	14184
the cord	14205
80 %	14229
This	14246
the formation of a central cavity	14262
the formation	14262
a central cavity	14279
some axons	14305
Animals injured in this manner	14328
Animals	14328
this manner	14347
symmetrical paraplegia	14364
hindlimb movement	14408
surgery	14444
SCI	14453
female Wistar rats -LRB- Laboratory Animal Center , University of Oviedo , Oviedo , Spain -RRB- , all matched for age -LRB- 12 weeks old -RRB- and weight -LRB- mean 250 g -RRB-	14472
female Wistar rats -LRB- Laboratory Animal Center , University of Oviedo , Oviedo , Spain -RRB-	14472
female Wistar rats	14472
Laboratory Animal Center , University of Oviedo , Oviedo , Spain	14492
Laboratory Animal Center	14492
University of Oviedo	14518
University	14518
Oviedo	14532
Oviedo , Spain	14540
all matched for age -LRB- 12 weeks old -RRB- and weight -LRB- mean 250 g -RRB-	14556
all	14556
age -LRB- 12 weeks old -RRB- and weight -LRB- mean 250 g -RRB-	14572
age	14572
12 weeks	14577
weight	14595
mean 250 g	14603
mean	14603
250 g	14608
The rats	14616
isoflurane inhalation -LRB- Esteve -RRB-	14646
isoflurane inhalation	14646
Esteve	14669
aseptic conditions	14684
the spinal cord	14704
laminectomy	14735
vertebral level T7	14750
fine iridectomy scissors -LRB- FST , Heidelberg , Germany -RRB-	14826
fine iridectomy scissors	14826
FST	14852
Heidelberg	14857
Germany	14869
SCI	14885
the rats	14890
the different treatment groups	14937
the spinal cord	14974
the tissue contraction	15002
enough room for scaffold insertion	15041
enough room	15041
scaffold insertion	15057
The scaffolds	15077
the site of spinal cord injury 5 min	15109
the site	15109
spinal cord injury 5 min	15121
injury -LRB- n = 8 per group -RRB-	15152
injury	15152
n = 8 per group	15160
n = 8	15160
n	15160
8	15162
group	15168
1 hour	15185
the operation	15198
the rats	15213
enrofloxacine -LRB- 8.5 mg/kg -RRB- once a day for 7 days and buprenorphine -LRB- 0.01 mg/kg -RRB- once a day	15240
enrofloxacine -LRB- 8.5 mg/kg -RRB-	15240
enrofloxacine	15240
8.5 mg/kg	15255
once a day for 7 days and buprenorphine -LRB- 0.01 mg/kg -RRB- once a day	15266
a day	15271
7 days and buprenorphine -LRB- 0.01 mg/kg -RRB-	15281
7 days and buprenorphine	15281
7 days	15281
buprenorphine	15292
0.01 mg/kg	15307
3 days	15334
The bladders of the animals	15342
The bladders	15342
the animals	15358
once a day	15392
they	15409
autonomic bladder function	15428
The rats	15456
a climate-controlled , pathogen-free animal house	15478
a12 h light-dark cycle	15544
Food and water	15568
Food	15568
water	15577
available ad libitum	15588
Experiments	15610
accordance	15640
the guidelines of the European Union -LRB- 86-609-EU -RRB- and Spanish regulations -LRB- BOE 67-8509-12 , 1988 -RRB-	15656
the guidelines	15656
the European Union -LRB- 86-609-EU -RRB- and Spanish regulations -LRB- BOE 67-8509-12 , 1988 -RRB-	15674
the European Union	15674
86-609-EU	15694
Spanish regulations	15709
BOE 67-8509-12	15730
1988	15746
Experimental protocols	15753
the Committee for Animal Care and Handling of the University of Oviedo	15798
the Committee	15798
Animal Care and Handling	15816
the University of Oviedo	15844
the University	15844
Oviedo	15862
Animal treatment groups The following in vivo treatment groups were established : Group 1 -LRB- G1 -RRB- , SCI-only : rats subjected to SCI	15870
Animal treatment groups	15870
The following	15894
vivo	15911
treatment groups	15916
Group 1 -LRB- G1 -RRB- , SCI-only : rats subjected to SCI	15951
Group 1 -LRB- G1 -RRB- , SCI-only	15951
Group 1	15951
G1	15960
SCI-only	15965
rats subjected to SCI	15975
rats	15975
SCI	15993
Group 2 -LRB- G2 -RRB- , SCI + scaffold : rats subjected to SCI and then treated with a cell-free scaffold .	16013
Group 2 -LRB- G2 -RRB- , SCI + scaffold	16013
Group 2	16013
G2	16022
SCI + scaffold	16027
scaffold	16033
rats subjected to SCI and then treated with a cell-free scaffold	16043
rats	16043
SCI	16061
a cell-free scaffold	16087
Group 3 -LRB- G3 -RRB- , SCI with cell	16109
Group 3 -LRB- G3 -RRB-	16109
Group 3	16109
G3	16118
SCI with cell	16123
SCI	16123
cell	16132
scaffold : rats subjected to SCI and then treated with a scaffold seeded with ADSCs and OECs	16144
scaffold	16144
rats subjected to SCI and then treated with a scaffold seeded with ADSCs and OECs	16154
rats	16154
SCI	16172
a scaffold seeded with ADSCs and OECs	16198
a scaffold	16198
ADSCs and OECs	16221
BBB	16246
Overall motor performance of the animals	16255
Overall motor performance	16255
the animals	16284
the BBB locomotor rating scale	16315
slight modifications -LRB- Basso et al. , 1995 -RRB-	16351
slight modifications	16351
Basso	16373
et al. , 1995	16379
et al.	16379
1995	16387
Rats	16394
place on a methacrylate walkway 1 m long	16404
place	16404
a methacrylate walkway 1 m long	16413
a methacrylate walkway	16413
1 m	16436
6.2 cm	16449
The runway	16462
top of an inclined mirror -LRB- 60 ° angle -RRB-	16487
top	16487
an inclined mirror -LRB- 60 ° angle -RRB-	16494
an inclined mirror	16494
60 ° angle	16514
the observation of hind-limb movements	16535
the observation	16535
hind-limb movements	16554
Each animal	16575
the runway	16599
three times	16610
each testing session	16626
the animals	16648
two observers blind to the treatment -LRB- the test was performed in a double-blinded manner -RRB-	16689
two observers	16689
the treatment -LRB- the test was performed in a double-blinded manner -RRB-	16712
the treatment	16712
the test	16727
a double-blinded manner	16753
Hind-limb locomotion	16779
0 -LRB- no observable hind-limb movement -RRB-	16816
0	16816
no observable hind-limb movement	16819
21 points -LRB- normal movement -RRB-	16856
21 points	16856
normal movement	16867
The scale	16885
the sequence of recovering motor features	16911
the sequence	16911
recovering motor features	16927
the same	16961
the original score	16986
rats	17012
their tails early	17035
the recovery process	17056
an additional 0.5 points	17078
a raised tail position -LRB- Demjen et al. , 2004 -RRB-	17118
a raised tail position	17118
Demjen	17142
et al. , 2004	17149
et al.	17149
2004	17157
All animals groups	17164
day 0 after SCI and once per week thereafter	17198
day 0	17198
SCI	17210
week	17227
13 weeks post injury	17249
13 weeks	17249
Rats	17271
a video camera	17296
their performance	17335
digitalized videos played at one-quarter speed	17372
digitalized videos	17372
one-quarter speed	17401
every treated group , n = 8 except in G2 on day 14 post-injury	17423
every treated group	17423
n = 8 except in G2 on day 14 post-injury	17444
n	17444
= 8 except in G2 on day 14 post-injury	17445
8	17446
G2 on day 14	17458
G2	17458
day 14	17464
the n	17484
audiovisual problems	17503
Histological and immunohistochemical analysis The animals in the different treatment groups	17525
Histological and immunohistochemical analysis The animals	17525
Histological and immunohistochemical analysis	17525
The animals	17571
the different treatment groups	17586
90 days	17633
surgery	17647
the animals	17665
saline solution	17711
ice-cold 4 % paraformaldehyde	17740
The entire spinal cords	17770
an additional 48-72 h in the same fixative	17828
an additional 48-72 h	17828
the same fixative	17853
the spinal cords	17878
EDTA solution -LRB- 10 % , Panreac -RRB- for 10 days	17912
EDTA solution -LRB- 10 % , Panreac -RRB-	17912
EDTA solution	17912
10 %	17927
Panreac	17932
10 days	17945
the EDTA solution replenished each day	17958
the EDTA solution	17958
each day	17988
The spinal cords	17998
approximately 2 cm lengths centered at the injury site analyzed	18034
approximately 2 cm lengths	18034
the injury site analyzed	18073
the injury site	18073
decalcification	18105
the spinal cords	18122
a graded series of ethanol dilutions and embedded in paraffin	18158
series of ethanol dilutions	18167
series	18167
ethanol dilutions	18177
Sections 20 μm thick	18221
Sections	18221
20 μm	18230
a microtome -LRB- model H310 ; Micron , Waldorf , Germany -RRB-	18262
a microtome	18262
model H310 ; Micron , Waldorf , Germany	18275
model H310	18275
Micron , Waldorf , Germany	18287
xylene	18332
an ethanol series	18354
PBS	18387
Some of the sections	18392
Some	18392
the sections	18400
glass slides for histological observations	18429
glass slides	18429
histological observations	18446
H&E and Sirius red staining	18478
H&E	18478
Sirius red staining	18486
immunohistochemical studies	18511
the sections	18540
1 % H2O2 for 30 min	18569
1 % H2O2	18569
30 min	18581
PBS	18605
endogenous peroxidase activity	18619
incubation with primary antibodies	18658
incubation	18658
primary antibodies	18674
possible background staining	18694
sections	18749
al	18762
30 min in 5 % BSA in PBS	18771
30 min	18771
5 % BSA in PBS	18781
5 % BSA	18781
PBS	18791
the anti-tyrosine hydroxylase primary antibody	18807
slides	18855
citrate buffer -LRB- pH 6 -RRB- in a pressure cooker	18891
citrate buffer -LRB- pH 6 -RRB-	18891
citrate buffer	18891
pH 6	18907
a pressure cooker	18916
The primary antibodies used	18935
The primary antibodies	18935
mouse anti-ß-III tubulin monoclonal antibody -LRB- 1:30000 ; Sigma-Aldrich -RRB- , mouse anti-glial fibrillary acidic protein -LRB- GFAP -RRB- polyclonal antibody -LRB- 1:15000 ; BD Bioscience -RRB- , mouse anti-dopamine ß-hydroxylase monoclonal antibody -LRB- 1:5000 ; Millipore -RRB- , mouse anti-ßgalactosidase polyclonal antibody -LRB- 1:15000 ; Millipore -RRB- , mouse anti-tyrosine hydroxylase monoclonal antibody -LRB- 1:1000 ; Millipore -RRB- , mouse anti-neurofilament 200 monoclonal antibody -LRB- 1:5000 , Sigma-Aldrich -RRB- , and mouse anti-GAP-43 monoclonal antibody -LRB- 1:5000 ; Santa Cruz Biotechnology , Heidelberg , Germany -RRB-	18968
mouse anti-ß-III tubulin monoclonal antibody -LRB- 1:30000 ; Sigma-Aldrich -RRB-	18968
mouse anti-ß-III tubulin	18968
monoclonal antibody -LRB- 1:30000 ; Sigma-Aldrich -RRB-	18993
monoclonal antibody	18993
1:30000 ; Sigma-Aldrich	19014
1:30000	19014
Sigma-Aldrich	19023
mouse anti-glial fibrillary acidic protein -LRB- GFAP -RRB- polyclonal antibody -LRB- 1:15000 ; BD Bioscience -RRB- , mouse anti-dopamine ß-hydroxylase monoclonal antibody -LRB- 1:5000 ; Millipore -RRB- , mouse anti-ßgalactosidase polyclonal antibody -LRB- 1:15000 ; Millipore -RRB- , mouse anti-tyrosine hydroxylase monoclonal antibody -LRB- 1:1000 ; Millipore -RRB- , mouse anti-neurofilament 200 monoclonal antibody -LRB- 1:5000 , Sigma-Aldrich -RRB- , and mouse anti-GAP-43 monoclonal antibody -LRB- 1:5000 ; Santa Cruz Biotechnology , Heidelberg , Germany -RRB-	19039
mouse anti-glial fibrillary acidic protein -LRB- GFAP -RRB- polyclonal antibody -LRB- 1:15000 ; BD Bioscience -RRB-	19039
mouse anti-glial fibrillary acidic protein -LRB- GFAP -RRB- polyclonal antibody	19039
1:15000 ; BD Bioscience	19110
1:15000	19110
BD Bioscience	19119
mouse anti-dopamine ß-hydroxylase monoclonal antibody -LRB- 1:5000 ; Millipore -RRB-	19135
mouse anti-dopamine ß-hydroxylase monoclonal antibody	19135
1:5000 ; Millipore	19190
1:5000	19190
Millipore	19198
mouse anti-ßgalactosidase polyclonal antibody -LRB- 1:15000 ; Millipore -RRB-	19210
mouse anti-ßgalactosidase polyclonal antibody	19210
1:15000 ; Millipore	19257
1:15000	19257
Millipore	19266
mouse anti-tyrosine hydroxylase monoclonal antibody -LRB- 1:1000 ; Millipore -RRB-	19278
mouse anti-tyrosine hydroxylase monoclonal antibody	19278
mouse anti-tyrosine hydroxylase	19278
monoclonal antibody	19310
1:1000 ; Millipore	19331
1:1000	19331
Millipore	19339
mouse anti-neurofilament 200 monoclonal antibody -LRB- 1:5000 , Sigma-Aldrich -RRB-	19351
mouse anti-neurofilament	19351
200 monoclonal antibody -LRB- 1:5000 , Sigma-Aldrich -RRB-	19376
200 monoclonal antibody	19376
1:5000	19401
Sigma-Aldrich	19409
mouse anti-GAP-43 monoclonal antibody -LRB- 1:5000 ; Santa Cruz Biotechnology , Heidelberg , Germany -RRB-	19429
mouse anti-GAP-43 monoclonal antibody	19429
1:5000 ; Santa Cruz Biotechnology	19468
1:5000	19468
Santa Cruz Biotechnology	19476
Heidelberg , Germany	19502
Heidelberg	19502
Germany	19514
The sections	19524
these primary antibodies overnight at 4 °C in a humid chamber	19557
these primary antibodies overnight	19557
4 °C in a humid chamber	19595
4 °C	19595
a humid chamber	19602
further rinsing in PBS	19625
further rinsing	19625
PBS	19644
the sections	19649
the secondary antibody conjugated to peroxidase -LRB- Dako -RRB- for 30 min at room temperature in a humid chamber	19694
the secondary antibody	19694
peroxidase -LRB- Dako -RRB- for 30 min	19731
peroxidase -LRB- Dako -RRB-	19731
peroxidase	19731
Dako	19743
30 min	19753
room temperature in a humid chamber	19763
room temperature	19763
a humid chamber	19783
The antibody complex	19800
the REAL EnVision Detection system kit -LRB- Dako -RRB-	19851
the REAL EnVision Detection system kit	19851
Dako	19891
This kit	19898
a DAB-like chromogen	19912
All sections	19934
hematoxylin	19972
sections	19993
a hydrophobic medium -LRB- Entellan ; Merck -RRB-	20018
a hydrophobic medium	20018
Entellan ; Merck	20040
Entellan	20040
Merck	20050
Observations and photographs	20058
a Olympus BX-41 microscope	20109
a digital camera -LRB- Olympus -RRB- and the results analyzed using the equipment 's image analysis software	20147
a digital camera -LRB- Olympus -RRB-	20147
a digital camera	20147
Olympus	20165
the results analyzed using the equipment 's image analysis software	20178
the results	20178
the equipment 's image analysis software	20205
the equipment 's	20205
Statistical analysis	20246
statistical analysis	20271
we	20292
the program Graphpad InStat	20300
Windows	20332
Data for the different groups	20341
Data	20341
the different groups	20350
unpaired two-tailed one-way analysis of variance -LRB- ANOVA -RRB-	20388
unpaired two-tailed one-way analysis	20388
variance -LRB- ANOVA -RRB-	20428
variance	20428
ANOVA	20438
a Student 's ttest	20454
a Student 's	20454
Data	20473
means	20494
S.E.M. Figures	20502
significant differences	20531
the discussion of the data	20567
the discussion	20567
the data	20585
The level of significance	20595
The level	20595
significance	20608
p	20632
Results Table 1 .	20641
Results	20641
Table 1	20649
Sirius red and immunohistochemical staining	20658
the three treatment groups	20722
Fig. 1 .	20751
Fig.	20751
1	20756
Scanning electron microphotographs of cross sections showing the microstructure of : -LRB- A -RRB- the albumin scaffold , -LRB- B -RRB- adipose-derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB-	20759
Scanning electron microphotographs	20759
cross sections	20797
the microstructure of : -LRB- A -RRB- the albumin scaffold , -LRB- B -RRB- adipose-derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB-	20820
the microstructure	20820
-LRB- A -RRB- the albumin scaffold , -LRB- B -RRB- adipose-derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB-	20843
-LRB- A -RRB- the albumin scaffold , -LRB- B -RRB- adipose-derived stem cells -LRB- ADSCs -RRB-	20843
-LRB- A -RRB- the albumin scaffold , -LRB- B -RRB- adipose-derived stem cells	20843
-LRB- A -RRB- the albumin scaffold , -LRB- B -RRB-	20843
-LRB- A -RRB-	20843
the albumin scaffold	20847
B	20870
adipose-derived stem cells	20873
ADSCs	20901
olfactory ensheathing cells -LRB- OECs -RRB-	20912
olfactory ensheathing cells	20912
OECs	20941
the scaffold	20958
Fig. 2 .	20973
Fig.	20973
2	20978
Effect of the scaffold on the nuclear morphology of adipose-derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB- .	20981
Effect	20981
the scaffold on the nuclear morphology	20991
the scaffold	20991
the nuclear morphology	21007
adipose-derived stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB-	21033
adipose-derived stem cells	21033
ADSCs	21061
olfactory ensheathing cells	21072
OECs	21101
the cells	21125
the scaffold for 7 days	21138
the scaffold	21138
7 days	21155
cell nuclei	21163
the DNA-binding fluorescent	21208
DAPI	21240
the autofluorescence of the scaffold	21251
the autofluorescence	21251
the scaffold	21275
A	21292
A. Control -LRB- scaffold alone -RRB- .	21296
A. Control	21296
scaffold	21308
B. Scaffold	21325
ADSCs and OECs	21349
the cell adipose-derived stem cells -LRB- ADSCs -RRB- , and olfactory ensheathing cells -LRB- OECs -RRB-	21386
the cell adipose-derived stem cells -LRB- ADSCs -RRB-	21386
the cell	21386
adipose-derived stem cells -LRB- ADSCs -RRB-	21395
adipose-derived stem cells	21395
ADSCs	21423
olfactory ensheathing cells -LRB- OECs -RRB-	21435
olfactory ensheathing cells	21435
OECs	21464
7 days of in vitro incubation	21476
7 days	21476
incubation	21495
the scaffold	21509
Control -LRB- scaffold alone -RRB- -LRB- C -RRB- , ADSCs stained with vimentin -LRB- D -RRB- and OECs stained with p75 -LRB- E -RRB-	21523
Control -LRB- scaffold alone -RRB-	21523
Control	21523
scaffold	21532
C	21549
ADSCs stained with vimentin -LRB- D -RRB-	21553
ADSCs	21553
vimentin -LRB- D -RRB-	21572
vimentin	21572
D	21582
OECs stained with p75 -LRB- E -RRB-	21589
OECs stained with p75	21589
OECs	21589
p75	21607
E	21612
Fig. 3 .	21617
Fig.	21617
3	21622
Motor function improvement in response to the cell-loaded albumin scaffold .	21625
Motor function improvement	21625
response	21655
the cell-loaded albumin scaffold	21667
Plot	21701
the scores obtained in the modified BBB locomotor test	21712
the scores	21712
the modified BBB locomotor test	21735
once a week	21767
90 days	21784
spinal cord injury and treatment	21798
spinal cord injury	21798
treatment	21821
all time points from 45 days post-injury	21835
all time points	21835
45 days	21856
the rate of improvement for G3	21877
the rate	21877
improvement for G3	21889
improvement	21889
G3	21905
the rate observed in G1 -LRB- * p < 0.05 -RRB-	21940
the rate	21940
G1	21961
p <	21966
p	21966
<	21967
0.05	21968
Values	21975
the means	21992
S.E.M. G1	22004
SCI-only	22015
G2 : SCI + scaffold .	22025
G2	22025
SCI + scaffold	22029
scaffold	22035
G3	22045
SCI with cell	22049
SCI	22049
cell	22058
scaffold	22070
Fig. 4 .	22081
Fig.	22081
4	22086
Hematoxylin/eosin -LRB- H&E -RRB- staining of 20 μm-thick longitudinal sections of specimens from SCI-only group -LRB- G1 , A -RRB- , SCI + scaffold -LRB- G2 , B -RRB- , and SCI with cell	22089
Hematoxylin/eosin -LRB- H&E -RRB- staining	22089
Hematoxylin/eosin -LRB- H&E -RRB-	22089
Hematoxylin/eosin	22089
H&E	22108
20 μm-thick longitudinal sections of specimens from SCI-only group -LRB- G1 , A -RRB- , SCI + scaffold -LRB- G2 , B -RRB- , and SCI with cell	22125
20 μm-thick longitudinal sections of specimens from SCI-only group -LRB- G1 , A -RRB- , SCI + scaffold -LRB- G2 , B -RRB- ,	22125
20 μm-thick longitudinal sections	22125
specimens from SCI-only group -LRB- G1 , A -RRB- , SCI + scaffold -LRB- G2 , B -RRB- ,	22162
specimens from SCI-only group	22162
specimens	22162
SCI-only group	22177
G1 , A	22193
G1	22193
A	22196
SCI + scaffold -LRB- G2 , B -RRB-	22200
SCI + scaffold	22200
scaffold	22206
G2 , B	22216
G2	22216
B	22219
SCI with cell	22227
SCI	22227
cell	22236
scaffold group -LRB- G3 , C -RRB-	22248
scaffold group	22248
G3 , C	22264
G3	22264
C	22267
A. Histological appearance of the central spinal cord cavity -LRB- black arrow -RRB- in G1 , 90 days after SCI .	22271
A. Histological appearance	22271
the central spinal cord cavity	22301
black arrow	22333
G1 , 90 days after SCI	22349
G1	22349
90 days after SCI	22353
90 days	22353
SCI	22367
B.	22372
Ninety days	22375
SCI and treatment	22393
SCI	22393
treatment	22401
the spaces at the site of injury	22412
the spaces	22412
the site of injury	22426
the site	22426
injury	22438
cells	22462
The albumin scaffold -LRB- red arrows -RRB-	22469
The albumin scaffold	22469
red arrows	22491
cells	22542
C.	22549
Ninety days	22552
SCI and treatment	22570
SCI	22570
treatment	22578
the spaces at the site of injury	22589
the spaces	22589
the site of injury	22603
the site	22603
injury	22615
ADSCs and OECs	22639
The albumin scaffold -LRB- red arrows -RRB-	22655
The albumin scaffold	22655
red arrows	22677
cells	22728
Fig. 5 .	22736
Fig.	22736
5	22741
Immunohistochemical staining of central cord cavities in rats 90 days after SCI and treatment .	22744
Immunohistochemical staining	22744
central cord cavities in rats 90 days	22776
central cord cavities	22776
rats	22801
90 days	22806
SCI and treatment	22820
SCI	22820
treatment	22828
All sections 20 μm-thick longitudinal .	22839
All sections	22839
20 μm-thick longitudinal	22852
20	22852
A-D	22878
SCIonly group -LRB- G1 -RRB- .	22883
SCIonly group -LRB- G1 -RRB-	22883
group -LRB- G1 -RRB-	22891
group	22891
G1	22898
E-H .	22903
SCI with cell	22908
SCI	22908
cell	22917
scaffold group -LRB- G3 -RRB-	22929
scaffold group	22929
G3	22945
the partially degraded scaffold in these images	22955
the partially degraded scaffold	22955
these images	22990
A , E. Glial cells showing positivity for GFAP	23004
, E. Glial cells showing positivity for GFAP	23005
, E. Glial cells	23005
E.	23007
positivity for GFAP	23030
positivity	23030
GFAP	23045
G1	23062
G3	23077
B , F. Neuronal cells and fibers showing positivity for GAP-43	23081
B	23081
F. Neuronal cells	23084
fibers showing positivity for GAP-43	23106
fibers	23106
positivity for GAP-43	23121
positivity	23121
GAP-43	23136
the injury site within the neoformed tissue in G3	23158
the injury site	23158
the neoformed tissue in G3	23181
the neoformed tissue	23181
G3	23205
G1	23220
C , G. Neuronal cells and fibers showing positivity for ß-III tubulin	23224
C	23224
G. Neuronal cells	23227
fibers showing positivity for ß-III tubulin	23249
fibers	23249
positivity for ß-III tubulin	23264
positivity	23264
ß-III tubulin	23279
the injury site	23308
the neoformed tissue in G3	23331
the neoformed tissue	23331
G3	23355
Representative longitudinal sections showing positivity for ß-III tubulin in the zones immediately rostral and caudal to the lesion site in G1 .	23359
Representative longitudinal sections	23359
positivity	23404
ß-III tubulin in the zones immediately rostral and caudal to the lesion site in G1	23419
ß-III tubulin	23419
the zones immediately rostral and caudal to the lesion site in G1	23436
the zones	23436
the lesion site in G1	23480
the lesion site	23480
G1	23499
D , H. Neurons and astroglial cells showing positivity for ß-galactosidase	23503
D	23503
H. Neurons	23506
astroglial cells showing positivity for ß-galactosidase	23521
astroglial cells	23521
positivity for ß-galactosidase	23546
positivity	23546
ß-galactosidase	23561
the neoformed tissue in G3	23596
the neoformed tissue	23596
G3	23620
G1	23635
Microstructure of the scaffold and morphology of ADSCs and OECs	23640
Microstructure	23640
the scaffold and morphology of ADSCs and OECs	23658
the scaffold and morphology	23658
ADSCs and OECs	23689
the scaffold The surface features of the albumin scaffold were observed by SEM	23716
the scaffold	23716
The surface features of the albumin scaffold	23729
The surface features	23729
the albumin scaffold	23753
SEM	23791
ADSCs and OECs , recognized according to their morphology ,	23796
ADSCs and OECs	23796
their morphology	23836
the scaffold	23879
The structure of the three-dimensional scaffold	23893
The structure	23893
the three-dimensional scaffold	23910
Fig. 1A	23956
Pore diameter	23965
50 to 150 μm -LRB- Fig. 1 -RRB-	23991
50 to 150 μm	23991
Fig. 1	24005
an irregular sized and shaped sheet-like structure	24020
an irregular	24020
sheet-like structure	24050
all	24096
This	24127
suitable spaces for cells	24141
suitable spaces	24141
cells	24161
the scaffold	24180
SEM observation of the cells incubated in the scaffold for 7 days	24194
SEM observation	24194
the cells incubated in the scaffold for 7 days	24213
the cells	24213
the scaffold for 7 days	24236
the scaffold	24236
7 days	24253
OECs and ADSCs	24274
the scaffold -LRB- Fig. 1B -RRB-	24300
the scaffold	24300
Fig. 1B	24314
Survival and characteristics of ADSCs and OECs when cultured in the scaffold The effect of the scaffold on cell viability	24324
Survival and characteristics	24324
ADSCs and OECs	24356
the scaffold	24388
The effect of the scaffold on cell viability	24401
The effect	24401
the scaffold on cell viability	24415
the scaffold	24415
cell viability	24431
DNA staining	24464
DAPI	24483
the ADSCs and OECs for 7 days in the scaffold	24506
the ADSCs and OECs	24506
7 days in the scaffold	24529
7 days	24529
the scaffold	24539
almost all cell nuclei -LRB- 99 ± 3 % -RRB-	24553
all cell nuclei -LRB- 99 ± 3 % -RRB-	24560
all cell	24560
nuclei -LRB- 99 ± 3 % -RRB-	24569
nuclei	24569
99 ± 3 %	24577
99	24577
3 %	24580
regular contours	24588
size , which is a characteristic of live cells -LRB- Fig. 2A , B -RRB-	24633
size	24633
a characteristic of live cells -LRB- Fig. 2A , B -RRB-	24648
a characteristic	24648
live cells -LRB- Fig. 2A , B -RRB-	24668
live cells	24668
Fig. 2A , B	24680
Fig. 2A	24680
B	24688
the cells	24698
immunohistochemical staining for vimentin and p75	24730
immunohistochemical staining	24730
vimentin and p75	24763
Almost all ADSCs	24781
vimentin positive -LRB- Fig. 2D -RRB-	24803
vimentin	24803
Fig. 2D	24822
OECs	24836
p75 -LRB- Fig. 2E -RRB-	24859
p75	24859
Fig. 2E	24864
Locomotor function The SCI model used	24874
Locomotor function	24874
The SCI model	24893
Demjen et al. , 2004	24943
Demjen	24943
et al.	24950
2004	24958
SCI	24973
symmetric paraplegia in the hind-limbs	24984
symmetric paraplegia	24984
the hind-limbs	25008
We	25024
multiple aspects of spontaneous locomotion using the modified BBB locomotor score -LRB- Basso et al. , 1995 -RRB-	25038
multiple aspects	25038
spontaneous locomotion using the modified BBB locomotor score -LRB- Basso et al. , 1995 -RRB-	25058
spontaneous locomotion	25058
the modified BBB locomotor score -LRB- Basso et al. , 1995 -RRB-	25087
the modified BBB locomotor score	25087
Basso	25121
et al. , 1995	25127
et al.	25127
1995	25135
day one after injury	25145
day one	25145
injury	25159
no variations in scores	25167
no variations	25167
scores	25184
the three groups of animals	25211
the three groups	25211
animals	25231
all animals suffering complete paraplegia and a lack of response to sensory stimuli to the hind-limbs -LRB- scores were 0 -RRB-	25245
all animals	25245
complete paraplegia and a lack of response	25267
complete paraplegia	25267
a lack of response	25291
a lack	25291
response	25301
sensory stimuli	25313
the hind-limbs	25332
scores	25348
0	25360
days 7 and 35 post-SCI	25372
days 7	25372
35 post-SCI	25383
the modified BBB score	25396
the SCI with cell	25432
the SCI	25432
cell	25445
scaffold group -LRB- G3 -RRB-	25457
scaffold group	25457
G3	25473
the scores for the control groups -LRB- G1 , SCI-only and G2 , SCI + scaffold -RRB-	25502
the scores	25502
the control groups -LRB- G1 , SCI-only and G2 , SCI + scaffold -RRB-	25517
the control groups	25517
G1 , SCI-only and G2	25537
G1	25537
SCI-only	25541
G2	25554
SCI + scaffold	25558
SCI	25558
scaffold	25564
no case	25587
the difference	25599
clinical progress and locomotor function at each time point from 45 days post-injury	25636
clinical progress and locomotor function	25636
each time point from 45 days post-injury	25680
each time point	25680
45 days	25701
SCI	25750
cell seeded scaffold rats , compared to controls : 6.3 ± 1.8 in SCI-only and 5.4 ± 2.2 in SCI + scaffold -LRB- Fig. 3 -RRB-	25759
cell seeded scaffold rats	25759
controls : 6.3 ± 1.8 in SCI-only and 5.4 ± 2.2 in SCI + scaffold -LRB- Fig. 3 -RRB-	25798
controls : 6.3 ± 1.8 in SCI-only and 5.4 ± 2.2	25798
controls	25798
6.3	25808
1.8 in SCI-only and 5.4	25814
1.8	25814
SCI-only and 5.4	25821
SCI-only	25821
5.4	25834
± 2.2	25838
SCI + scaffold -LRB- Fig. 3 -RRB-	25847
SCI	25847
scaffold	25853
Fig. 3	25863
45 days	25872
treatment	25886
SCI with cell	25897
SCI	25897
cell	25906
scaffold rats	25918
mean modified BBB scores of 8.3 ± 0.2 -LRB- the maximum score of 21.5 indicates no motor defects -RRB-	25939
mean modified BBB scores	25939
8.3 ± 0.2 -LRB- the maximum score of 21.5 indicates no motor defects -RRB-	25967
8.3 ± 0.2	25967
the maximum score of 21.5	25976
the maximum score	25976
21.5	25997
no motor defects	26012
the scores	26043
the group	26077
score	26097
90 days of follow-up	26109
90 days	26109
follow-up	26120
9.1	26134
0.1	26138
Scores for the control groups	26143
Scores	26143
the control groups	26154
those recorded at 45 days : 5.7 ± 0.6 and 4.3 ± 1.1 respectively -LRB- Fig. 3 -RRB-	26189
those	26189
45 days : 5.7 ± 0.6 and 4.3 ± 1.1 respectively -LRB- Fig. 3 -RRB-	26207
45 days : 5.7 ± 0.6 and 4.3 ± 1.1 respectively	26207
45 days : 5.7 ± 0.6 and 4.3 ± 1.1	26207
45 days	26207
5.7	26216
0.6 and 4.3	26220
0.6	26220
4.3	26228
± 1.1	26231
Fig. 3	26250
figure 3	26277
no significant differences between control groups	26287
no significant differences	26287
control groups	26322
any of the treatment times	26354
any	26354
the treatment times	26361
overall locomotor recovery in the treatment group SCI with cell	26392
overall locomotor recovery	26392
the treatment group SCI	26422
cell	26451
scaffold	26463
the control groups	26505
the slopes of plots of scores against time	26541
the slopes	26541
plots of scores against time	26555
plots	26555
scores against time	26564
scores	26564
time	26579
Histological analysis To follow the course of spinal injury and the process of nervous tissue regeneration in vivo	26585
Histological analysis	26585
the course of spinal injury and the process of nervous tissue regeneration in vivo	26617
the course of spinal injury	26617
the course	26617
spinal injury	26631
the process of nervous tissue regeneration in vivo	26649
the process	26649
nervous tissue regeneration in vivo	26664
nervous tissue regeneration	26664
vivo	26695
histological studies	26701
all groups of animals	26740
all groups	26740
animals	26754
their sacrifice 90 days post-injury	26768
their sacrifice	26768
90 days	26784
H&E staining	26813
it	26826
SCI-only	26845
the spinal cord central cavity	26859
many areas empty of cells	26894
many areas	26894
cells	26914
some zones	26930
bundles of tissue	26967
bundles	26967
tissue	26978
there	26990
no evidence of significant tissue regeneration -LRB- Fig. 4A -RRB-	27000
no evidence	27000
significant tissue regeneration -LRB- Fig. 4A -RRB-	27015
significant tissue regeneration	27015
Fig. 4A	27048
contrast	27061
SCI + scaffold -LRB- Fig. 4B -RRB-	27074
SCI	27074
scaffold	27080
Fig. 4B	27090
SCI with cell	27107
SCI	27107
cell	27116
scaffold group -LRB- Fig. 4C -RRB- the cord central cavity was completely filled with cells 90 days post-injury	27128
scaffold group	27128
Fig. 4C	27144
the cord central cavity	27153
cells 90 days post-injury	27204
cells	27204
90 days	27210
A visible reduction in the volume of residual scaffold	27231
A visible reduction	27231
the volume of residual scaffold	27254
the volume	27254
residual scaffold	27268
the	27302
period	27314
reabsorption of the scaffold and replacement with new tissue	27333
reabsorption	27333
the scaffold and replacement with new tissue	27349
the scaffold and replacement	27349
new tissue	27383
Sirius red	27395
the extent of scar tissue formation	27427
the extent	27427
scar tissue formation	27441
the site of injury	27470
the site	27470
injury	27482
collagen positive in all animal groups at 90 days post-injury -LRB- see Table 1 -RRB-	27493
collagen	27493
all animal groups at 90 days post-injury -LRB- see Table 1 -RRB-	27514
all animal groups	27514
90 days post-injury -LRB- see Table 1 -RRB-	27535
90 days post-injury	27535
Table 1	27560
This	27570
the motor improvement observed in SCI with cell	27589
the motor improvement	27589
SCI	27623
cell	27632
scaffold group	27644
collagen scar inhibition	27678
Immunohistochemical analysis	27704
it	27738
the presence of scaffold plus cells	27767
the presence	27767
scaffold plus cells	27783
scaffold	27783
cells	27797
collagen synthesis	27819
SCI	27844
we	27849
the classic concept of the formation of a glial scar	27861
the classic concept	27861
the formation of a glial scar	27884
the formation	27884
a glial scar	27901
the injured spinal cord tissue using an antibody against the astrocyte marker GFAP	27917
the injured spinal cord tissue	27917
an antibody against the astrocyte marker GFAP	27954
an antibody	27954
the astrocyte marker GFAP	27974
The results of this analysis	28001
The results	28001
this analysis	28016
rats in group SCI with cell	28044
rats	28044
group SCI with cell	28052
group SCI	28052
cell	28067
scaffold 90 days post-injury	28079
scaffold	28079
90 days	28088
GFAPnegative cells	28115
the cord cavity and close	28142
the injury site -LRB- rostral and caudal -RRB- -LRB- Fig. 5E -RRB-	28171
the injury site -LRB- rostral and caudal -RRB-	28171
the injury site	28171
rostral and caudal	28188
rostral	28188
caudal	28200
Fig. 5E	28209
SCIonly rats	28227
sites immediately -LRB- rostral and caudal -RRB-	28262
sites immediately	28262
sites	28262
rostral and caudal	28281
rostral	28281
caudal	28293
the point of injury , which confirms the presence of glial scar in this control group -LRB- Fig. 5A -RRB-	28309
the point	28309
injury , which confirms the presence of glial scar in this control group -LRB- Fig. 5A -RRB-	28322
injury	28322
the presence of glial scar in this control group -LRB- Fig. 5A -RRB-	28345
the presence	28345
glial scar in this control group -LRB- Fig. 5A -RRB-	28361
glial scar	28361
this control group -LRB- Fig. 5A -RRB-	28375
this control group	28375
Fig. 5A	28395
contrast	28408
cord cells in SCI + scaffold	28418
cord cells	28418
SCI + scaffold	28432
SCI	28432
scaffold	28438
GFAP-immunostaining at the lesion site -LRB- images not shown -RRB-	28465
GFAP-immunostaining	28465
the lesion site	28488
images not shown	28505
images	28505
These observations	28524
the scaffold	28556
glial scar formation	28595
the scaffold plus cells	28625
the scaffold	28625
cells	28643
this glial scar	28665
the origin of newly formed tissue	28692
the origin	28692
newly formed tissue	28706
the spinal cord cavities of the treatment groups	28729
the spinal cord cavities	28729
the treatment groups	28757
we	28779
different specific antibodies	28787
the newly formed tissue	28846
a bridge that permitted the passage of ascending and descending axons	28883
a bridge	28883
the passage of ascending and descending axons	28907
the passage	28907
axons	28947
we	28954
axons expressing tyrosine hydroxylase , neurofilament 200 , dopamine ßhydroxylase and GAP-43 , as possible components of regeneration -LRB- see Table 1 -RRB-	28968
axons	28968
tyrosine hydroxylase , neurofilament 200 , dopamine ßhydroxylase and GAP-43	28985
tyrosine hydroxylase	28985
neurofilament 200	29007
dopamine ßhydroxylase	29026
GAP-43	29052
possible components of regeneration -LRB- see Table 1 -RRB-	29063
possible components	29063
regeneration	29086
Table 1	29104
SCI with cell	29120
SCI	29120
cell	29129
scaffold	29141
positive immunostaining	29157
antibodies	29185
tyrosine hydroxylase and neurofilament 200 inside	29204
tyrosine hydroxylase	29204
neurofilament 200 inside	29229
the scaffold -LRB- images not shown -RRB-	29265
the scaffold	29265
images not shown	29279
images	29279
cells in the cords of the SCI with cell	29309
cells	29309
the cords of the SCI with cell	29318
the cords	29318
the SCI with cell	29331
the SCI	29331
cell	29344
scaffold animals	29356
GAP-43 positive rostral to the scaffold -LRB- injury site -RRB-	29378
GAP-43 positive rostral	29378
the scaffold -LRB- injury site -RRB-	29405
the scaffold	29405
injury site	29419
immunopositive staining in the space where the initial injury took place , which was filled with the cell-loaded scaffolds ,	29439
immunopositive staining	29439
the space where the initial injury took place	29466
the space	29466
the initial injury	29482
place	29506
the cell-loaded scaffolds	29535
the newly formed tissue	29576
neurons or neuronal elements	29610
neurons	29610
neuronal elements	29621
SCI-only cords	29640
tyrosine hydroxylase , neurofilament 200 , and GAP-43	29673
tyrosine hydroxylase	29673
neurofilament 200	29695
GAP-43	29718
rostral	29730
caudal zones	29741
the injury site -LRB- Fig. 5B -RRB-	29765
the injury site	29765
Fig. 5B	29782
contrast	29795
cord cells in SCI + scaffold animals	29805
cord cells	29805
SCI + scaffold animals	29819
SCI	29819
scaffold animals	29825
very few neurofilament 200 , tyrosine hydroxylase , and GAP-43 positive fibers	29852
very few neurofilament 200	29852
tyrosine hydroxylase	29880
GAP-43 positive fibers	29906
the injury site -LRB- images not shown -RRB-	29932
the injury site	29932
images not shown	29949
images	29949
all groups	29971
cord cells	29983
dopamine ß-hydroxylase negative at the injury site -LRB- images not shown -RRB-	29999
dopamine ß-hydroxylase	29999
the injury site -LRB- images not shown -RRB-	30034
the injury site	30034
images not shown	30051
images	30051
the presence of neural and astroglial cells	30090
the presence	30090
neural and astroglial cells	30106
the site of injury	30137
the site	30137
injury	30149
we	30157
neurons expressing ß-III tubulin -LRB- adult neurons -RRB- , GAP - 43 -LRB- neurons observed during developmental growth -RRB- and neurons and astroglial cells expressing ß-galactosidase -LRB- see Table 1 -RRB-	30174
neurons	30174
ß-III tubulin -LRB- adult neurons -RRB- , GAP - 43 -LRB- neurons observed during developmental growth -RRB- and neurons and astroglial cells expressing ß-galactosidase -LRB- see Table 1 -RRB-	30193
ß-III tubulin -LRB- adult neurons -RRB- , GAP	30193
ß-III tubulin	30193
adult neurons	30208
GAP	30224
43 -LRB- neurons observed during developmental growth -RRB-	30229
43	30229
neurons observed during developmental growth	30233
neurons	30233
developmental growth	30257
neurons and astroglial cells expressing ß-galactosidase -LRB- see Table 1 -RRB-	30283
neurons	30283
astroglial cells expressing ß-galactosidase -LRB- see Table 1 -RRB-	30295
astroglial cells expressing ß-galactosidase	30295
astroglial cells	30295
ß-galactosidase	30323
Table 1	30344
Cord cells in all the treatment groups	30354
Cord cells	30354
all the treatment groups	30368
immunopositive staining	30400
the ß-III tubulin antibody	30428
there	30465
very few ß-III tubulinpositive cells in SCI-only and SCI + scaffold groups compared to the SCI with cell	30476
few ß-III	30481
tubulinpositive cells in SCI-only and SCI	30491
tubulinpositive cells	30491
SCI-only and SCI	30516
scaffold groups compared to the SCI with cell	30535
scaffold groups	30535
the SCI with cell	30563
the SCI	30563
cell	30576
scaffold group -LRB- Fig. 5C , G -RRB-	30588
scaffold group	30588
Fig. 5C , G	30604
Fig. 5C	30604
G	30612
the cords in SCI + scaffold and SCI with cell	30626
the cords	30626
SCI + scaffold and SCI with cell	30639
SCI + scaffold	30639
scaffold	30645
SCI with cell	30658
SCI	30658
cell	30667
scaffold animals	30679
positive immunostaining	30703
the GAP-43 antibody	30731
the injury site	30754
their ß-III tubulin staining pattern	30782
cord cells in SCI-only animals	30820
cord cells	30820
SCI-only animals	30834
Fig. 5B , F	30873
Fig. 5B	30873
F	30881
Cord cells in SCI with cell	30885
Cord cells	30885
SCI with cell	30899
SCI	30899
cell	30908
scaffold group	30920
the control groups , which were both negative for this antibody -LRB- Fig. 5D , H -RRB-	30992
the control groups	30992
this antibody -LRB- Fig. 5D , H -RRB-	31041
this antibody	31041
Fig. 5D , H	31056
Fig. 5D	31056
H	31064
Discussion Recent research efforts	31069
the field of SCI therapy	31107
the field	31107
SCI therapy	31120
new biodegradable scaffolds	31159
a permissive and stimulating environment for nerve regeneration -LRB- Madigan et al. , 2009 ; Straley et al. , 2010 -RRB-	31197
a permissive and stimulating environment	31197
nerve regeneration -LRB- Madigan et al. , 2009 ; Straley et al. , 2010 -RRB-	31242
nerve regeneration	31242
Madigan	31262
et al. , 2009 ; Straley et al. , 2010	31270
et al.	31270
2009 ; Straley et al.	31278
2009	31278
Straley et al.	31284
Straley	31284
et al.	31292
2010	31300
The main goal of the present study	31307
The main goal	31307
the present study	31324
the performance of a solid human serum-derived scaffold developed by our research group	31356
the performance	31356
a solid human serum-derived scaffold developed by our research group	31375
a solid human serum-derived scaffold	31375
our research group	31425
a previous study	31448
we	31466
the use of this albumin scaffold	31478
the use	31478
this albumin scaffold	31489
bone defects using cultured osteoblasts in a rat model -LRB- Gallego et al. , 2010 -RRB-	31521
bone defects	31521
osteoblasts in a rat model -LRB- Gallego et al. , 2010 -RRB-	31549
osteoblasts	31549
a rat model -LRB- Gallego et al. , 2010 -RRB-	31564
a rat model	31564
Gallego	31577
et al. , 2010	31585
et al.	31585
2010	31593
Similar tissue engineered implants	31600
Similar tissue	31600
implants	31626
the problem	31649
the toxicity of the crosslinking agent glutaraldehyde	31666
the toxicity	31666
the crosslinking agent glutaraldehyde	31682
cell culture	31736
The lyophilization step after crosslinking incorporated in our technique	31750
The lyophilization step	31750
our technique	31809
the toxic properties of this agent -LRB- Gallego et al. , 2010 -RRB-	31841
the toxic properties	31841
this agent -LRB- Gallego et al. , 2010 -RRB-	31865
this agent	31865
Gallego	31877
et al. , 2010	31885
et al.	31885
2010	31893
The findings of this study	31900
The findings	31900
this study	31916
the scaffold developed	31940
the scaffold	31940
an appropriate substrate for nerve tissue regeneration	31966
an appropriate substrate	31966
nerve tissue regeneration	31995
an autologous scaffold	32052
The scaffold	32076
the advantage that it is easy and nonexpensive to produce	32098
the advantage	32098
it	32117
Pore structure	32157
scaffolds	32207
tissue engineering	32221
High porosity and wellconnected	32241
High porosity	32241
wellconnected	32259
good mass transfer properties and increase cell viability	32286
good mass transfer properties	32286
increase cell viability	32320
A porous scaffold microstructure with minimal pore size	32345
A porous scaffold microstructure	32345
minimal pore size	32383
tissue ingrowth -LRB- Zeltinger et al. , 2001 -RRB-	32430
tissue ingrowth	32430
Zeltinger	32447
et al. , 2001	32457
et al.	32457
2001	32465
The pore size of our scaffold	32472
The pore size	32472
our scaffold	32489
50 to 150 μm	32538
a larger pore size observed in longitudinal sections than cross sections of scaffold	32556
a larger pore size	32556
longitudinal sections	32587
cross sections of scaffold	32614
cross sections	32614
scaffold	32632
These	32642
shape	32676
a suitable architecture	32720
cell penetration	32748
the three-dimensional structure of the scaffold used in our study	32772
the three-dimensional structure	32772
the scaffold used in our study	32807
the scaffold	32807
our study	32828
a suitable framework	32847
guiding axon regeneration across its large gaps or cavities	32872
guiding axon regeneration	32872
its large gaps or cavities	32905
sufficient space	32945
ADSC neurotransdifferentiation	32966
Various types of cell	32998
Various types	32998
cell	33015
cell therapy approaches to SCI , including Schwann cells -LRB- Ramon - Cueto et al. , 2000 ; Verdu et al. , 2003 ; Garcia-Alias et al. , 2004 -RRB- and bone marrow stem cells -LRB- BMSCs -RRB- -LRB- Chopp and Li , 2002 ; Zurita and Vaquero , 2006 -RRB-	33038
cell therapy	33038
SCI	33065
Schwann cells -LRB- Ramon - Cueto et al. , 2000 ; Verdu et al. , 2003 ; Garcia-Alias et al. , 2004 -RRB- and bone marrow stem cells -LRB- BMSCs -RRB- -LRB- Chopp and Li , 2002 ; Zurita and Vaquero , 2006 -RRB-	33080
Schwann cells	33080
Ramon	33095
Cueto et al. , 2000 ; Verdu et al. , 2003 ; Garcia-Alias et al. , 2004 -RRB- and bone marrow stem cells -LRB- BMSCs -RRB- -LRB- Chopp and Li , 2002 ; Zurita and Vaquero , 2006	33102
Cueto	33102
et al. , 2000 ; Verdu et al. , 2003 ; Garcia-Alias et al. , 2004 -RRB- and bone marrow stem cells -LRB- BMSCs -RRB- -LRB- Chopp and Li , 2002 ; Zurita and Vaquero , 2006	33108
et al. , 2000	33108
et al.	33108
2000	33116
Verdu et al. , 2003	33122
Verdu	33122
et al. , 2003	33128
et al.	33128
2003	33136
Garcia-Alias et al. , 2004 -RRB- and bone marrow stem cells -LRB- BMSCs -RRB- -LRB- Chopp and Li , 2002	33142
Garcia-Alias et al. , 2004 -RRB-	33142
Garcia-Alias	33142
et al.	33155
2004	33163
bone marrow stem cells -LRB- BMSCs -RRB- -LRB- Chopp and Li , 2002	33173
bone marrow stem cells -LRB- BMSCs -RRB-	33173
bone marrow stem cells	33173
BMSCs	33197
Chopp and Li	33205
2002	33219
Zurita and Vaquero , 2006	33225
Zurita and Vaquero	33225
2006	33245
harvesting bone marrow -LRB- BM -RRB-	33258
harvesting bone marrow	33258
BM	33282
a highly invasive procedure	33289
researchers	33318
the use of adipose tissue	33345
the use	33345
adipose tissue	33356
an alternative rich source of MSC	33374
an alternative rich source	33374
MSC	33404
effect	33412
ADSCs	33420
numerous properties that make them ideal candidates for cell transplant therapy after SCI	33431
numerous properties	33431
them	33461
ideal candidates for cell transplant therapy	33466
ideal candidates	33466
cell transplant therapy	33487
SCI	33517
These cells	33522
characteristics with BMSCs	33540
characteristics	33540
BMSCs	33561
immune rejection -LRB- Wang et al. , 2007 -RRB-	33587
immune rejection	33587
Wang	33605
et al. , 2007	33610
et al.	33610
2007	33618
they	33629
the advantage that they can be easily obtained from subcutaneous adipose tissue , expanded and stored -LRB- Zuk et al. , 2001 ; Yarak and Okamoto , 2010 -RRB-	33639
the advantage	33639
they	33658
subcutaneous adipose tissue	33691
Zuk et al. , 2001 ; Yarak and Okamoto , 2010	33741
Zuk	33741
et al. , 2001 ; Yarak and Okamoto , 2010	33745
et al. , 2001	33745
et al.	33745
2001	33753
Yarak and Okamoto , 2010	33759
Yarak and Okamoto	33759
2010	33778
contrast	33788
OECs	33798
the olfactory bulb and olfactory lamina propria with the limitation of the scarce availability of functional cells	33821
the olfactory bulb and olfactory lamina propria	33821
the limitation of the scarce availability of functional cells	33874
the limitation	33874
the scarce availability of functional cells	33892
the scarce availability	33892
functional cells	33919
Wang et al. -LRB- 2007 -RRB-	33937
Wang et al.	33937
Wang	33937
et al.	33942
2007	33950
OECs	33970
a variety of growth factors that promote the neural differentiation of ADSCs in three-dimensional scaffolds in vitro	33983
a variety	33983
growth factors	33996
the neural differentiation of ADSCs in three-dimensional scaffolds	34024
the neural differentiation	34024
ADSCs in three-dimensional scaffolds	34054
ADSCs	34054
three-dimensional scaffolds	34063
the complementary biological properties of OECs and ADSCs	34107
the complementary biological properties	34107
OECs and ADSCs	34150
we	34166
both cell types	34185
our rat model of SCI	34204
our rat model	34204
SCI	34221
Our	34226
tests	34239
both OECs and ADSCs	34259
OECs	34264
ADSCs	34273
their viability and phenotype	34290
seed the scaffold	34333
seed	34333
the scaffold	34338
7 days in the scaffolds	34375
7 days	34375
the scaffolds	34385
these	34400
the injured rats	34424
Wang et al. -LRB- Wang et al. , 2007 -RRB- , in vivo	34455
Wang et al. -LRB- Wang et al. , 2007 -RRB-	34455
Wang	34455
et al. -LRB- Wang et al. , 2007 -RRB-	34460
et al.	34460
Wang	34468
et al. , 2007	34473
et al.	34473
2007	34481
vivo	34491
neuro-differentiation	34496
place	34524
20-30 days	34530
The neuro-differentiation of ADSCs and their survival and migration from the	34556
The neuro-differentiation	34556
ADSCs and their survival and migration from the	34585
ADSCs	34585
their survival and migration from the	34595
their survival and migration	34595
the	34629
site	34641
future studies	34678
Our functional in vivo results	34694
Our functional	34694
vivo results	34712
modified BBB	34741
scores -LRB- Basso et al. , 1995 -RRB- recorded in our three experimental groups at 90 days post-injury	34762
scores	34762
Basso	34770
et al. , 1995	34776
et al.	34776
1995	34784
our three experimental groups	34802
90 days	34835
the motor recovery observed in SCI with cell	34862
the motor recovery	34862
SCI	34893
cell	34902
scaffold group -LRB- G3 -RRB- over that recorded in controls at this time point	34914
scaffold group -LRB- G3 -RRB-	34914
scaffold group	34914
G3	34930
that recorded in controls at this time point	34939
that	34939
controls at this time point	34956
controls	34956
this time point	34968
Other authors -LRB- Ramon-Cueto et al. , 2000 ; Lu et al. , 2002 -RRB-	35001
Other authors	35001
Ramon-Cueto	35016
et al. , 2000 ; Lu et al. , 2002	35028
et al.	35028
2000 ; Lu et al.	35036
2000	35036
Lu et al.	35042
Lu	35042
et al.	35045
2002	35053
the transplantation of OECs or BMSCs into injured spinal cord tissue in rats with paraplegia	35078
the transplantation	35078
OECs or BMSCs into injured spinal cord tissue in rats with paraplegia	35101
OECs or BMSCs	35101
injured spinal cord tissue in rats with paraplegia	35120
injured spinal cord tissue	35120
rats with paraplegia	35150
rats	35150
paraplegia	35160
a clear functional recovery that starts a few weeks after transplantation -LRB- Vaquero et al. , 2006 -RRB-	35180
a clear functional recovery	35180
a few weeks	35220
transplantation -LRB- Vaquero et al. , 2006 -RRB-	35238
transplantation	35238
Vaquero	35255
et al. , 2006	35263
et al.	35263
2006	35271
Our SCI with cell	35278
Our SCI	35278
cell	35291
scaffold animals	35303
improved locomotor scores early after SCI -LRB- up to 21 days postinjury -RRB-	35327
improved locomotor scores	35327
SCI -LRB- up to 21 days postinjury -RRB-	35365
SCI	35365
up to 21 days	35370
controls -LRB- SCI-only , SCI + scaffold -RRB- , which later stabilized at around 9 -LRB- from 45 days post-injury -RRB-	35401
controls -LRB- SCI-only , SCI + scaffold -RRB-	35401
controls	35401
SCI-only , SCI + scaffold	35411
SCI-only	35411
SCI + scaffold	35421
scaffold	35427
around 9 -LRB- from 45 days post-injury -RRB-	35464
around 9	35464
45 days	35479
This score	35501
plantar placement of the paw with weight support in stance only or occasional , frequent or consistent weight	35522
plantar placement	35522
the paw with weight support in stance only or occasional , frequent or consistent weight	35543
the paw	35543
weight support in stance only or occasional , frequent or consistent weight	35556
weight support in stance only	35556
weight support	35556
stance only	35574
occasional , frequent or consistent weight	35589
dorsal stepping and no plantar stepping	35641
dorsal stepping	35641
dorsal	35641
no plantar stepping	35661
no plantar	35661
contrast	35685
SCI-only group , in which injured animals were left untreated ,	35695
SCI-only group	35695
injured animals	35720
stable mean modified BBB scores of approximately 5 , and SCI + scaffold group	35771
stable mean	35771
BBB scores of approximately 5 , and SCI + scaffold group	35792
BBB scores	35792
approximately 5 , and SCI + scaffold group	35806
approximately 5	35806
SCI + scaffold group	35827
scaffold group	35833
a slightly lower score -LRB- approximately 4 -RRB-	35857
a slightly lower score	35857
approximately 4	35881
These results	35899
those of several studies -LRB- Ramon-Cueto et al. , 1998 ; Deng et al. , 2006 ; Zurita et al. , 2008 -RRB- in which transplantation of either BMSCs or OECs alone was found to promote functional recovery after SCI	35933
those	35933
several studies -LRB- Ramon-Cueto et al. , 1998 ; Deng et al. , 2006 ; Zurita et al. , 2008 -RRB- in which transplantation of either BMSCs or OECs alone was found to promote functional recovery after SCI	35942
several studies	35942
Ramon-Cueto et al. , 1998 ; Deng et al. , 2006 ; Zurita et al. , 2008	35959
Ramon-Cueto	35959
et al. , 1998 ; Deng et al. , 2006 ; Zurita et al. , 2008	35971
et al. , 1998	35971
et al.	35971
1998	35979
Deng et al. , 2006	35985
Deng	35985
et al. , 2006	35990
et al.	35990
2006	35998
Zurita et al. , 2008	36004
Zurita	36004
et al. , 2008	36011
et al.	36011
2008	36019
transplantation of either BMSCs or OECs	36034
transplantation	36034
either BMSCs or OECs	36053
functional recovery	36101
SCI	36127
Deng et al. , 2008	36142
Deng et al.	36142
Deng	36142
et al.	36147
2008	36155
co-transplantation of OECs and BMSCs	36175
co-transplantation	36175
OECs and BMSCs	36197
the functional recovery of SCI in rats , probably	36245
the functional recovery	36245
SCI	36272
rats	36279
such a way	36297
OECs	36313
the neuronal differentiation of implanted BMSCs	36343
the neuronal differentiation	36343
implanted BMSCs	36375
possible mechanisms	36405
the observed functional recovery	36436
we	36470
several histology and immunohistochemistry techniques	36478
histological studies on our SCI-untreated control animals	36539
histological studies	36539
our SCI-untreated control animals	36563
the persistence of the typical post-traumatic spinal cord cavity	36606
the persistence	36606
the typical post-traumatic spinal cord cavity	36625
90 days	36671
injury	36685
Zurita and Vaquero	36693
2006	36713
contrast	36723
the injured animals treated with cell seeded scaffold -LRB- G3 -RRB- or a SCI + scaffold -LRB- G2 -RRB-	36736
the injured animals	36736
cell seeded scaffold -LRB- G3 -RRB- or a SCI + scaffold -LRB- G2 -RRB-	36769
cell	36769
scaffold -LRB- G3 -RRB- or a SCI + scaffold -LRB- G2 -RRB-	36781
scaffold -LRB- G3 -RRB- or a SCI	36781
scaffold -LRB- G3 -RRB-	36781
scaffold	36781
G3	36791
a SCI	36798
scaffold -LRB- G2 -RRB-	36806
scaffold	36806
G2	36816
the post-SCI cavity	36821
cells	36868
This	36875
the cells implanted within the scaffold	36894
the cells	36894
the scaffold	36921
the spinal cord cavity	36957
new nervous tissue that could act as a bridge for the passage of descending axons	36989
new nervous tissue	36989
a bridge for the passage of descending axons	37026
a bridge	37026
the passage of descending axons	37039
the passage	37039
descending axons	37054
this idea	37081
the infilled spinal cord cavity observed after the implant of the scaffold alone	37108
the	37108
spinal cord cavity observed after the implant of the scaffold alone	37121
spinal cord cavity	37121
the	37155
the scaffold	37170
A possible explanation	37190
call-cells	37221
this	37240
the lesion site in response	37261
the lesion site	37261
response	37280
injury	37292
effect	37303
it	37311
these new cells	37328
-LRB- call-cells -RRB-	37353
the spinal cord	37369
the damaged area , where it is assumed they replace injured cells -LRB- McDonald and Becker , 2003 -RRB-	37400
the damaged area	37400
it	37424
they	37438
injured cells -LRB- McDonald and Becker , 2003 -RRB-	37451
injured cells	37451
McDonald and Becker , 2003	37466
McDonald	37466
Becker , 2003	37479
Becker	37479
2003	37487
the new scaffold	37500
a good support for these call-cells	37530
a good support	37530
these call-cells	37549
The classic concept that scar formation -LRB- connective tissue scar or glial scar -RRB- in the injured spinal cord tissue might impede the passage of regenerated axons from one extreme of the lesion to the other	37567
The classic concept	37567
scar formation -LRB- connective tissue scar or glial scar -RRB- in the injured spinal cord tissue	37592
scar formation -LRB- connective tissue scar or glial scar -RRB-	37592
scar formation	37592
connective tissue scar or glial scar	37608
connective tissue scar	37608
glial scar	37634
the injured spinal cord tissue	37649
the passage of regenerated axons	37693
the passage	37693
regenerated axons	37708
one extreme of the lesion	37731
one extreme	37731
the lesion	37746
the other	37760
90 days	37825
scaffold	37839
this time point	37860
fibrous tissue identified by Sirius red staining	37877
fibrous tissue	37877
Sirius red staining	37906
the margins of the spinal cord cavity in all the treatment groups	37943
the margins	37943
the spinal cord cavity in all the treatment groups	37958
the spinal cord cavity	37958
all the treatment groups	37984
immunostaining for GFAP in SCI + scaffold and SCI with cell	38019
immunostaining	38019
GFAP in SCI + scaffold and SCI with cell	38038
GFAP	38038
SCI + scaffold and SCI with cell	38046
SCI + scaffold	38046
scaffold	38052
SCI with cell	38065
SCI	38065
cell	38074
scaffold groups	38086
the presence of astrocytes at the injury site or caudal or rostral	38119
the presence	38119
astrocytes at the injury site or caudal or rostral	38135
astrocytes	38135
the injury site or caudal or rostral	38149
this point 3 months	38189
this point	38189
3 months	38200
SCI	38215
this time point	38223
the tissue repair process	38240
a steady state	38286
contrast	38305
large populations of GFAPpositive astrocytes	38315
large populations	38315
GFAPpositive astrocytes	38336
the injury site and caudal and rostral	38377
this site in SCI-only	38419
this site	38419
SCI-only	38432
SCI	38447
Some authors	38452
downregulation of GFAP	38479
downregulation	38479
GFAP	38497
reactive astrocytes induced by OECs transplanted into lesioned spinal cords -LRB- Verdu et al. , 2001 -RRB-	38505
reactive astrocytes	38505
OECs transplanted into lesioned spinal cords -LRB- Verdu et al. , 2001 -RRB-	38536
OECs	38536
lesioned spinal cords -LRB- Verdu et al. , 2001 -RRB-	38559
lesioned spinal cords	38559
Verdu	38582
et al. , 2001	38588
et al.	38588
2001	38596
The absence of glial scar tissue observed in the spinal cords of the scaffold-treated animals	38603
The absence	38603
glial scar tissue observed in the spinal cords of the scaffold-treated animals	38618
glial scar tissue	38618
the spinal cords of the scaffold-treated animals	38648
the spinal cords	38648
the scaffold-treated animals	38668
the albumin scaffold	38711
reactive astrocytes	38770
their reactivity	38800
a protective environment	38830
Animals in SCI with cell	38856
Animals	38856
SCI with cell	38867
SCI	38867
cell	38876
scaffold group	38888
immunopositive staining	38910
antibodies against neural and astroglial cells	38938
antibodies	38938
neural and astroglial cells	38957
the injury site	38988
the newly formed tissue	39021
neurons and glial cells	39054
neurons	39054
glial cells	39066
this neotissue	39089
SCI that completely filled the spinal cord cavity permitted the passage of descending and ascending neurons	39119
SCI	39119
the spinal cord cavity	39146
the passage of descending and ascending neurons	39179
the passage	39179
neurons	39219
the specific antibodies used	39243
the specific antibodies	39243
SCI-only group	39273
ß-III tubulin-positive fibers	39295
the slight locomotor recovery observed in control rats	39341
the slight locomotor recovery	39341
control rats	39383
the neoformation of the axons detected	39419
the neoformation	39419
the axons detected	39439
the axons	39439
the scaffold	39468
functional recovery	39513
it	39534
the ingrowth of a variety of cell types	39569
the ingrowth	39569
a variety of cell types	39585
a variety	39585
cell types	39598
glial scar inhibition	39626
a support for callcells	39670
a support	39670
callcells	39684
These results	39695
the scaffold itself provides an adequate environment for both the survival and differentiation , at least partly , of these call-cells that fill the cord cavity	39717
the scaffold	39717
itself	39730
an adequate environment for both the survival and differentiation , at least	39746
an adequate environment for both the survival and differentiation	39746
an adequate environment	39746
both the survival and differentiation	39774
these call-cells that fill the cord cavity	39833
these call-cells	39833
the cord cavity	39860
it	39885
most of these newborn cells -LRB- call-cells -RRB-	39911
most	39911
these newborn cells -LRB- call-cells -RRB-	39919
these newborn cells	39919
call-cells	39940
the first few weeks	39963
the injured spinal cord	39991
a suitable environment -LRB- Johansson et al. , 1999 ; Ceccatelli et al. , 2004 -RRB-	40035
a suitable environment	40035
Johansson	40059
et al. , 1999 ; Ceccatelli et al. , 2004	40069
et al.	40069
1999 ; Ceccatelli et al.	40077
1999	40077
Ceccatelli et al.	40083
Ceccatelli	40083
et al.	40094
2004	40102
contrast	40112
animals undergoing transplant of the scaffold containing both cells types	40122
animals	40122
transplant of the scaffold containing both cells types	40141
transplant	40141
the scaffold containing both cells types	40155
the scaffold	40155
cells types	40184
significantly improved motor function	40203
the remaining animals	40253
rats in SCI with cell	40282
rats	40282
SCI with cell	40290
SCI	40290
cell	40299
scaffold group that were still alive at 90 days post-injury continued to show recovery , as indicated by their modified BBB scores	40311
scaffold group	40311
90 days post-injury continued to show recovery , as indicated by their modified BBB scores	40351
90 days post-injury	40351
recovery	40389
their modified BBB scores	40415
the scaffold-alone	40451
a significant role	40485
glial scar formation	40516
the presence of both cells types in the scaffold	40538
the presence	40538
both cells types in the scaffold	40554
both cells types	40554
the scaffold	40574
the greatest recovery	40596
The mechanisms whereby the scaffold plus cells	40619
The mechanisms	40619
the scaffold plus cells	40642
the scaffold	40642
cells	40660
the functional recovery process	40686
further explored	40729
further	40729
conclusion	40750
our findings	40762
OECs and ADSCs	40802
this new human serum-derived spongy scaffold	40818
motor function recovery in SCI rats	40882
motor function recovery	40882
SCI rats	40909
future direction	40930
studies designed to test the safety and potential of this scaffold	40951
studies	40951
the safety and potential of this scaffold	40976
the safety and potential	40976
this scaffold	41004
Acknowledgements .	41020
This work	41039
FICYT PEST 08-12 and Obra Social y Cultural Cajastur	41066
FICYT PEST 08-12	41066
Obra Social y Cultural Cajastur	41087
The authors	41120
the assistance of	41144
the assistance	41144
Dra	41163
Aurora Astudillo and the staff of pathology unit of the HUCA , Dr. M. Nieto-Sampedro and E. Martín-López , Dra .	41168
Aurora Astudillo and the staff of pathology unit of the HUCA	41168
Aurora Astudillo	41168
the staff of pathology unit of the HUCA	41189
the staff	41189
pathology unit of the HUCA	41202
pathology unit	41202
the HUCA	41220
Dr. M. Nieto-Sampedro and E. Martín-López , Dra	41230
Dr. M. Nieto-Sampedro and E. Martín-López	41230
Dra	41273
Ana Martín - Villalba .	41278
Ana Martín	41278
Villalba	41290
References Arboleda D. , Forostyak S. , Jendelova P. , Marekova D. , Amemori T. , Pivonkova H. , Masinova K. and Sykova E. -LRB- 2011 -RRB- .	41301
References	41301
Arboleda D. , Forostyak S. , Jendelova P. , Marekova D. , Amemori T. , Pivonkova H. , Masinova K. and Sykova E. -LRB- 2011 -RRB-	41312
Arboleda D. , Forostyak S. , Jendelova P. , Marekova D. , Amemori T. , Pivonkova H. , Masinova K. and Sykova E.	41312
Arboleda D.	41312
Forostyak S.	41325
Jendelova P.	41339
Marekova D.	41353
Amemori T.	41366
Pivonkova H.	41378
Masinova K.	41392
Sykova E.	41408
2011	41419
Transplantation of predifferentiated adipose-derived stromal cells for the treatment of spinal cord injury .	41426
Transplantation	41426
predifferentiated adipose-derived stromal cells for the treatment	41445
predifferentiated adipose-derived stromal cells	41445
the treatment	41497
spinal cord injury	41514
Cell Mol .	41534
Cell	41534
Mol	41539
Neurobiol	41544
31 , 1113-1122 .	41555
31	41555
1113-1122	41559
Balentine J.D. -LRB- 1978 -RRB- .	41570
Balentine J.D.	41570
1978	41586
Pathology of experimental spinal cord trauma .	41593
Pathology	41593
experimental spinal cord trauma	41606
II	41639
Ultrastructure of axons and myelin .	41643
Ultrastructure	41643
axons and myelin	41661
axons	41661
myelin	41671
Lab .	41679
39 , 254-266 .	41692
39	41692
254-266	41696
Barnett S.C. and Riddell J.S. -LRB- 2004 -RRB- .	41705
Barnett S.C. and Riddell J.S.	41705
2004	41736
Olfactory Ensheathing Cells -LRB- OECs -RRB- and the treatment of CNS injury : advantages and possible caveats .	41743
Olfactory Ensheathing Cells -LRB- OECs -RRB- and the treatment of CNS injury	41743
Olfactory Ensheathing Cells -LRB- OECs -RRB-	41743
Olfactory Ensheathing Cells	41743
OECs	41772
the treatment of CNS injury	41782
the treatment	41782
CNS injury	41799
advantages and possible caveats	41811
advantages	41811
possible caveats	41826
J. Anat .	41844
204 , 57-67 .	41853
204	41853
57-67	41858
Basso D.M. , Beattie M.S. and Bresnahan J.C. -LRB- 1995 -RRB- .	41865
Basso D.M. , Beattie M.S. and Bresnahan J.C.	41865
1995	41910
A sensitive and reliable locomotor rating scale for open field testing in rats .	41917
A sensitive and reliable locomotor	41917
rating scale for open field testing in rats	41952
rating scale	41952
open field testing in rats	41969
open field testing	41969
rats	41991
J. Neurotrauma 12 , 1-21 .	41997
J.	41997
Neurotrauma 12 , 1-21	42000
Brazda N. and Müller H.W. -LRB- 2009 -RRB- .	42022
Brazda N. and Müller H.W.	42022
2009	42050
Pharmacological modification of the extracellular matrix to promote regeneration of the injured brain and spinal cord .	42057
Pharmacological modification	42057
the extracellular matrix	42089
regeneration of the injured brain and spinal cord	42125
regeneration	42125
the injured brain and spinal cord	42141
the injured brain	42141
spinal cord	42163
Prog .	42176
Brain Res .	42182
Brain	42182
Res	42188
175 , 269-281 .	42193
175	42193
269-281	42198
Busch S.A. and Silver J. -LRB- 2007 -RRB- .	42207
Busch S.A. and Silver J.	42207
2007	42233
The role of extracellular matrix in CNS regeneration .	42240
The role	42240
extracellular matrix	42252
CNS regeneration	42276
Curr .	42294
Opin	42300
Nerurobiol	42306
17 , 120-127 .	42318
17	42318
120-127	42322
Cadelli D.S. , Bandtlow C.E. and Schwab M.E. -LRB- 1992 -RRB- .	42331
Cadelli D.S. , Bandtlow C.E. and Schwab M.E.	42331
1992	42376
Oligodendrocyte and myelinassociated inhibitors of neurite outgrowth : their involvement in the lack of CNS regeneration .	42383
Oligodendrocyte and myelinassociated inhibitors of neurite outgrowth	42383
Oligodendrocyte and myelinassociated inhibitors	42383
neurite outgrowth	42434
their involvement in the lack of CNS regeneration	42453
their involvement	42453
the lack of CNS regeneration	42474
the lack	42474
CNS regeneration	42486
Exp .	42504
Neurol	42509
115 , 189 - 192 .	42517
115	42517
189 - 192	42522
Ceccatelli S. , Tamm C. , Sleeper E. and Orrenius S. -LRB- 2004 -RRB- .	42532
Ceccatelli S.	42532
Tamm C. , Sleeper E. and Orrenius S. -LRB- 2004 -RRB-	42547
Tamm C. , Sleeper E. and Orrenius S.	42547
Tamm C.	42547
Sleeper E.	42556
Orrenius S.	42571
2004	42584
Neural stem cells and cell death .	42591
Neural stem	42591
cells and cell death	42603
cells	42603
cell death	42613
Toxicol	42625
Lett	42634
149 , 59-66 .	42640
149	42640
59-66	42645
Chopp M. and Li Y. -LRB- 2002 -RRB- .	42652
Chopp M. and Li Y.	42652
2002	42672
Treatment of neural injury with marrow stromal cells .	42679
Treatment	42679
neural injury	42692
marrow stromal cells	42711
Lancet Neurol .	42733
1 , 92-100 .	42748
1	42748
92-100	42751
Collazos-Castro J.E. , Muñeton-Gomez V.C. and Nieto-Sampedro M. -LRB- 2005 -RRB- .	42759
Collazos-Castro J.E. , Muñeton-Gomez V.C. and Nieto-Sampedro M.	42759
2005	42823
Olfactory glia transplantation into cervical spinal cord contusion injuries .	42830
Olfactory glia transplantation	42830
cervical spinal cord contusion injuries	42866
J. Neurosurg .	42907
Spine 3 , 308-317 .	42921
Spine 3	42921
308-317	42930
Demjen D. , Klussmann S. , Kleber S. , Zuliani C. , Stieltjes B. , Metzger C. , Hirt U.A. , Walczak H. , Falk W. , Essig M. , Edler L. , Krammer P.H. , Martin-Villalba A. -LRB- 2004 -RRB- .	42939
Demjen D.	42939
Klussmann S. , Kleber S. , Zuliani C. , Stieltjes B. , Metzger C. , Hirt U.A. , Walczak H. , Falk W. , Essig M. , Edler L. , Krammer P.H.	42950
Klussmann S.	42950
Kleber S.	42964
Zuliani C.	42975
Stieltjes B.	42987
Metzger C.	43001
Hirt U.A.	43013
Walczak H.	43024
Falk W.	43036
Essig M.	43045
Edler L.	43055
Krammer P.H.	43065
Martin-Villalba A. -LRB- 2004 -RRB-	43079
Martin-Villalba A.	43079
2004	43099
Neutralization of CD95 ligand	43106
Neutralization	43106
CD95 ligand	43124
regeneration and functional recovery after spinal cord injury	43145
regeneration and functional recovery	43145
spinal cord injury	43188
Nat .	43208
Med	43213
10 , 389-395 .	43218
10	43218
389-395	43222
Deng Y.B. , Liu X.G. , Liu Z.G. , Liu X.L. , Liu Y. and Zhou G.Q. -LRB- 2006 -RRB- .	43231
Deng Y.B.	43231
Liu X.G. , Liu Z.G. , Liu X.L. , Liu Y. and Zhou G.Q. -LRB- 2006 -RRB-	43242
Liu X.G. , Liu Z.G. , Liu X.L. , Liu Y. and Zhou G.Q.	43242
Liu X.G.	43242
Liu Z.G.	43252
Liu X.L.	43262
Liu Y.	43272
Zhou G.Q.	43283
2006	43294
Implantation of BM mesenchymal stem cells into injured spinal cord	43301
Implantation	43301
BM mesenchymal stem cells	43317
injured spinal cord	43348
de novo neurogenesis and functional recovery : evidence from a study in rhesus monkeys	43376
de novo neurogenesis and functional recovery	43376
de novo neurogenesis	43376
functional recovery	43401
evidence from a study in rhesus monkeys	43422
evidence	43422
a study in rhesus monkeys	43436
a study	43436
rhesus monkeys	43447
Cytotherapy 8 , 210-214 .	43463
Cytotherapy 8	43463
210-214	43478
Deng Y.B. , Liu Y. , Zhu W.B. , Bi X.B. , Wang Y.Z. , Ye M.H. and Zhou G.Q. -LRB- 2008 -RRB- .	43487
Deng Y.B.	43487
Liu Y. , Zhu W.B. , Bi X.B. , Wang Y.Z. , Ye M.H. and Zhou G.Q. -LRB- 2008 -RRB-	43498
Liu Y.	43498
Zhu W.B.	43506
Bi X.B.	43516
Wang Y.Z.	43525
Ye M.H.	43536
Ye	43536
M.H.	43539
Zhou G.Q. -LRB- 2008 -RRB-	43548
Zhou G.Q.	43548
2008	43559
The co-transplantation of human bone marrow stromal cells and embryo olfactory ensheathing cells as a new approach to treat spinal cord injury in a rat model .	43566
The co-transplantation	43566
human bone marrow stromal cells and embryo olfactory ensheathing cells as a new approach	43592
human bone marrow stromal cells and embryo olfactory ensheathing cells	43592
bone marrow stromal cells	43598
a new approach	43666
spinal cord injury in a rat model	43690
spinal cord injury	43690
a rat model	43712
Cytotherapy 10 , 551-564 .	43725
Cytotherapy 10	43725
551-564	43741
Fawcett J.W. and Asher R.A. -LRB- 1999 -RRB- .	43750
Fawcett J.W. and Asher R.A.	43750
1999	43779
The glial scar and central nervous system repair .	43786
The glial scar and central nervous system repair	43786
The glial scar	43786
central nervous system repair	43805
Brain Res .	43836
Brain	43836
Res	43842
Bull .	43847
49 , 377-391 .	43853
49	43853
377-391	43857
Gallego L. , Junquera L. , Meana A. , Alvarez-Viejo M. amd Fresno M. -LRB- 2009 -RRB- .	43866
Gallego L.	43866
Junquera L. , Meana A.	43878
Junquera L.	43878
Meana A.	43891
Alvarez-Viejo M. amd Fresno M. -LRB- 2009 -RRB-	43901
Alvarez-Viejo M. amd Fresno M.	43901
2009	43933
Ectopic bone formation from mandibular osteoblasts	43940
Ectopic bone formation	43940
mandibular osteoblasts	43968
a novel human serum-derived albumin scaffold	44003
J. Biomater .	44049
Appl .	44062
25 , 367-381 .	44068
25	44068
367-381	44072
Gallego L. , Junquera L. , Garcia E. , Garcia V. , Alvarez-Viejo M. , Costilla S. , Fresno M.F. and Meana A. -LRB- 2010 -RRB- .	44081
Gallego L.	44081
Junquera L. , Garcia E. , Garcia V. , Alvarez-Viejo M. , Costilla S. , Fresno M.F. and Meana A. -LRB- 2010 -RRB-	44093
Junquera L. , Garcia E. , Garcia V. , Alvarez-Viejo M. , Costilla S. , Fresno M.F. and Meana A.	44093
Junquera L.	44093
Garcia E.	44106
Garcia V.	44117
Alvarez-Viejo M.	44128
Costilla S.	44146
Fresno M.F.	44159
Meana A.	44175
2010	44185
Repair of rat mandibular bone defects by alveolar osteoblasts in a novel plasma-derived albumin scaffold .	44192
Repair	44192
rat mandibular bone defects	44202
alveolar osteoblasts	44233
a novel plasma-derived albumin scaffold	44257
Tissue Eng .	44298
Tissue	44298
Eng	44305
16 , 1179-1187 .	44310
16	44310
1179-1187	44314
Garcia-Alias G. , Lopez-Vales R. , Fores J. , Navarro X. and Verdu E. -LRB- 2004 -RRB- .	44325
Garcia-Alias G.	44325
Lopez-Vales R. , Fores J. , Navarro X. and Verdu E. -LRB- 2004 -RRB-	44342
Lopez-Vales R. , Fores J. , Navarro X. and Verdu E.	44342
Lopez-Vales R.	44342
Fores J.	44358
Navarro X.	44368
Verdu E.	44383
2004	44393
Acute transplantation of olfactory ensheathing cells or Schwann cells	44400
Acute transplantation	44400
olfactory ensheathing cells or Schwann cells	44425
recovery	44479
spinal cord injury in the rat	44494
spinal cord injury	44494
the rat	44516
J. Neurosci .	44525
Res	44538
75 , 632-641 .	44543
75	44543
632-641	44547
Groves A.K. , Barnett S.C. , Franklin R.J. , Crang A.J. , Mayer M. , Blakemore W.F. and Noble M. -LRB- 1993 -RRB- .	44556
Groves A.K.	44556
Barnett S.C. , Franklin R.J. , Crang A.J. , Mayer M. , Blakemore W.F. and Noble M. -LRB- 1993 -RRB-	44569
Barnett S.C. , Franklin R.J. , Crang A.J. , Mayer M. , Blakemore W.F. and Noble M.	44569
Barnett S.C.	44569
Franklin R.J.	44583
Crang A.J.	44598
Mayer M.	44610
Blakemore W.F.	44620
Noble M.	44639
1993	44649
Repair of	44656
Repair	44656
lesions	44679
transplantation of purified O-2A progenitor cells	44690
transplantation	44690
purified O-2A progenitor cells	44709
Nature 362 , 453-455 .	44741
Nature 362	44741
453-455	44753
Gudiño-Cabera G. and Nieto-Sampedro M. -LRB- 1996 -RRB- .	44762
Gudiño-Cabera G. and Nieto-Sampedro M.	44762
1996	44802
Ensheathing cells : Large scale purification from adult olfactory bulb , freeze-preservation and migration of transplanted cells in adult brain .	44809
Ensheathing cells	44809
Large scale purification from adult olfactory bulb , freeze-preservation and migration of transplanted cells in adult brain	44828
Large scale purification	44828
adult olfactory bulb , freeze-preservation and migration	44858
transplanted cells in adult brain	44917
transplanted cells	44917
adult brain	44939
Neurol	44958
Neurosci	44966
10 , 25-34 .	44976
10	44976
25-34	44980
Jin K. , Mao X.O. , Batteur S. , Sun Y. and Greenberg D.A. -LRB- 2003 -RRB- .	44987
Jin K.	44987
Mao X.O. , Batteur S. , Sun Y. and Greenberg D.A. -LRB- 2003 -RRB-	44995
Mao X.O. , Batteur S. , Sun Y. and Greenberg D.A.	44995
Mao X.O.	44995
Batteur S.	45005
Sun Y.	45017
Greenberg D.A.	45028
2003	45044
Induction of neuronal markers in bone marrow cells : differential effects of growth factors and patterns of intracellular expression .	45051
Induction of neuronal markers in bone marrow cells	45051
Induction	45051
neuronal markers in bone marrow cells	45064
neuronal markers	45064
bone marrow cells	45084
differential effects of growth factors and patterns of intracellular expression	45103
differential effects	45103
growth factors and patterns	45127
intracellular expression	45158
Exp .	45184
Neurol	45189
84 , 78-89 .	45197
84	45197
78-89	45201
Johansson C.B. , Momma S. , Clarke D.L. , Risling M. , Lendahl U. and Frisen J. -LRB- 1999 -RRB- .	45208
Johansson C.B.	45208
Momma S. , Clarke D.L. , Risling M. , Lendahl U. and Frisen J. -LRB- 1999 -RRB-	45224
Momma S. , Clarke D.L. , Risling M. , Lendahl U. and Frisen J.	45224
Momma S.	45224
Clarke D.L.	45234
Risling M.	45247
Lendahl U.	45259
Frisen J.	45274
1999	45285
Identification of a neural stem cell in the adult mammalian central nervous system .	45292
Identification	45292
a neural stem cell	45310
the adult mammalian central nervous system	45332
Cell .	45376
96 , 25-34 .	45382
96	45382
25-34	45386
Kang S.K. , Lee D.H. , Bae Y.C. , Kim H.K. , Baik S.Y. and Jung J.S. -LRB- 2003 -RRB- .	45393
Kang S.K.	45393
Lee D.H. , Bae Y.C. , Kim H.K. , Baik S.Y. and Jung J.S. -LRB- 2003 -RRB-	45404
Lee D.H. , Bae Y.C. , Kim H.K. , Baik S.Y. and Jung J.S.	45404
Lee D.H.	45404
Bae Y.C.	45414
Kim H.K.	45424
Baik S.Y.	45434
Jung J.S.	45448
2003	45459
Improvement of neurological deficits by intracerebral transplantation of human adipose tissue-derived stromal cells after cerebral ischemia in rats .	45466
Improvement	45466
neurological deficits by intracerebral transplantation	45481
neurological deficits	45481
intracerebral transplantation	45506
human adipose tissue-derived stromal cells after cerebral ischemia	45539
human adipose tissue-derived stromal cells	45539
cerebral ischemia	45588
rats	45609
Exp .	45615
Neurol	45620
183 , 355-366 .	45628
183	45628
355-366	45633
Li C. , Li L. , Zhe-Yu C. , Li-Mei W. , Jun-LI Y. , Hai-Yan Q. , Chang-Lin L. and Cheng H. -LRB- 2004 -RRB- .	45642
Li C.	45642
Li L. , Zhe-Yu C. , Li-Mei W. , Jun-LI Y. , Hai-Yan Q. , Chang-Lin L. and Cheng H. -LRB- 2004 -RRB-	45649
Li L. , Zhe-Yu C. , Li-Mei W. , Jun-LI Y. , Hai-Yan Q. , Chang-Lin L. and Cheng H.	45649
Li L.	45649
Zhe-Yu C.	45656
Li-Mei W.	45667
Jun-LI Y.	45678
Hai-Yan Q.	45689
Chang-Lin L.	45701
Cheng H.	45718
2004	45728
Olfactory ensheating cells	45735
GDNF	45794
spinal cord repair	45810
Brain 127 , 535-549 .	45830
Brain 127	45830
535-549	45841
Lu J. , Feron F. , Mackay-Sim A. and Waite P.M. -LRB- 2002 -RRB- .	45850
Lu J.	45850
Feron F. , Mackay-Sim A. and Waite P.M. -LRB- 2002 -RRB-	45857
Feron F. , Mackay-Sim A. and Waite P.M.	45857
Feron F.	45857
Mackay-Sim A.	45867
Waite P.M.	45885
2002	45897
Olfactory ensheathing cells	45904
locomotor recovery	45940
delayed transplantation into transected spinal cord	45965
delayed transplantation	45965
transected spinal cord	45994
Brain 125 , 14-21 .	46018
Brain 125	46018
14-21	46029
Madigan N.N. , McMahon S. , O'Brien T. , Yaszemski M.J. and Windebank A.J. -LRB- 2009 -RRB- .	46036
Madigan N.N.	46036
McMahon S. , O'Brien T. , Yaszemski M.J. and Windebank A.J. -LRB- 2009 -RRB-	46050
McMahon S. , O'Brien T. , Yaszemski M.J. and Windebank A.J.	46050
McMahon S.	46050
O'Brien T.	46062
Yaszemski M.J.	46074
Windebank A.J.	46093
2009	46109
Current tissue engineering and novel therapeutic approaches to axonal regeneration following spinal cord injury using polymer scaffolds .	46116
Current tissue engineering and novel therapeutic approaches to axonal regeneration	46116
Current tissue engineering	46116
novel therapeutic approaches to axonal regeneration	46147
novel therapeutic approaches	46147
axonal regeneration	46179
spinal cord injury	46209
polymer scaffolds	46234
Respir	46253
Physiol	46261
Neurobiol	46270
169 , 183 - 199 .	46281
169	46281
183 - 199	46286
McDonald J.W. and Becker D. -LRB- 2003 -RRB- .	46296
McDonald J.W. and Becker D.	46296
2003	46325
Spinal cord injury : promising interventions and realistic goals .	46332
Spinal cord injury	46332
promising interventions and realistic goals	46352
promising interventions	46352
realistic goals	46380
Am	46397
J. Phys .	46401
Med	46410
Rehabil	46415
82 , S38-49 .	46424
82	46424
S38-49	46428
McGee A.W. and Strittmatter S.M. -LRB- 2003 -RRB- .	46436
McGee A.W. and Strittmatter S.M.	46436
2003	46470
The Nogo-66 receptor	46477
myelin inhibition of axon regeneration	46508
myelin inhibition	46508
axon regeneration	46529
Trends Neurosci .	46548
Trends	46548
Neurosci	46555
26 , 193-198 .	46565
26	46565
193-198	46569
Meana A. , Garcia E. , Garcia V. , Jorcano J.L. , del Rio M. , Larcher F. , Duarte B. and Holguin A. -LRB- 2008 -RRB- .	46578
Meana A.	46578
Garcia E. , Garcia V. , Jorcano J.L. , del Rio M. , Larcher F. , Duarte B. and Holguin A. -LRB- 2008 -RRB-	46588
Garcia E. , Garcia V. , Jorcano J.L. , del Rio M. , Larcher F. , Duarte B. and Holguin A.	46588
Garcia E.	46588
Garcia V.	46599
Jorcano J.L.	46610
del Rio M.	46624
Larcher F.	46636
Duarte B.	46648
Holguin A.	46662
2008	46674
Method for preparing threedimensional structures for tissue engineering .	46681
Method	46681
threedimensional structures	46702
tissue engineering	46734
WO/2008/119855 .	46754
Olson H.E. , Rooney G.E. , Gross L. , Nesbitt J.J. , Galvin K.E. , Knight A. , Chen B. , Yaszemski M.J. and Windebank A.J. -LRB- 2009 -RRB- .	46770
Olson H.E.	46770
Rooney G.E. , Gross L. , Nesbitt J.J. , Galvin K.E. , Knight A. , Chen B. , Yaszemski M.J. and Windebank A.J. -LRB- 2009 -RRB-	46782
Rooney G.E. , Gross L. , Nesbitt J.J. , Galvin K.E. , Knight A. , Chen B. , Yaszemski M.J. and Windebank A.J.	46782
Rooney G.E.	46782
Gross L.	46795
Nesbitt J.J.	46805
Galvin K.E.	46819
Knight A.	46832
Chen B.	46843
Yaszemski M.J.	46852
Windebank A.J.	46871
2009	46887
Neural stem cell - and Schwann cell-loaded biodegradable polymer scaffolds	46894
Neural stem cell	46894
Schwann cell-loaded biodegradable polymer scaffolds	46916
axonal regeneration in the transected spinal cord	46976
axonal regeneration	46976
the transected spinal cord	46999
Tissue Eng .	47027
Tissue	47027
Eng	47034
Part A. 15 , 1797-1805 .	47039
Part	47039
A. 15 , 1797-1805	47044
Radtke C. , Aizer A.A. , Agulian S.K. , Lankford K.L. , Vogt P.M. and Kocsis J.D. -LRB- 2009 -RRB- .	47062
Radtke C.	47062
Aizer A.A. , Agulian S.K. , Lankford K.L. , Vogt P.M. and Kocsis J.D. -LRB- 2009 -RRB-	47073
Aizer A.A. , Agulian S.K. , Lankford K.L. , Vogt P.M. and Kocsis J.D.	47073
Aizer A.A.	47073
Agulian S.K.	47085
Lankford K.L.	47099
Vogt P.M.	47114
Kocsis J.D.	47128
2009	47141
Transplantation of olfactory ensheathing cells	47148
Transplantation	47148
olfactory ensheathing cells	47167
peripheral nerve regeneration	47204
microsurgical nerve repair	47240
Brain Res .	47268
Brain	47268
Res	47274
1254 , 10-17 .	47279
1254	47279
10-17	47285
Raisman G. -LRB- 1985 -RRB- .	47292
Raisman G.	47292
1985	47304
Specialized neuroglial arrangement nay	47311
Specialized	47311
neuroglial arrangement nay	47323
the capacity of vomeronasal axons	47358
the capacity	47358
vomeronasal axons	47374
central neurons	47407
Neuroscience	47424
14 , 237-254 .	47438
14	47438
237-254	47442
Raisman G. -LRB- 2001 -RRB- .	47451
Raisman G.	47451
2001	47463
cells-another miracle cure	47492
spinal cord injury	47523
Nat .	47543
Rev. Neurosci .	47548
2 , 369-375 .	47563
2	47563
369-375	47566
Ramon-Cueto A. and Nieto-Sampedro M. -LRB- 1994 -RRB- .	47575
Ramon-Cueto A. and Nieto-Sampedro M.	47575
1994	47613
Regeneration into the spinal cord of transected dorsal root axons	47620
Regeneration	47620
the spinal cord of transected dorsal root axons	47638
the spinal cord	47638
transected dorsal root axons	47657
glia transplants	47713
Exp .	47731
Neurol	47736
127 , 232-244 .	47744
127	47744
232-244	47749
Ramon-Cueto A. , Plant G.W. , Avila J. and Bunge M.B. -LRB- 1998 -RRB- .	47758
Ramon-Cueto A.	47758
Plant G.W. , Avila J. and Bunge M.B. -LRB- 1998 -RRB-	47774
Plant G.W. , Avila J. and Bunge M.B.	47774
Plant G.W.	47774
Avila J.	47786
Bunge M.B.	47799
1998	47811
Longdistance axonal regeneration in the transected adult rat spinal cord	47818
Longdistance axonal regeneration	47818
the transected adult rat spinal cord	47854
olfactory ensheathing glia transplants	47906
J. Neurosci .	47946
18 , 3803-3815 .	47959
18	47959
3803-3815	47963
Ramon-Cueto A. , Cordero M.I. , Santos-Benito F.F. and Avila J. -LRB- 2000 -RRB- .	47974
Ramon-Cueto A.	47974
Cordero M.I. , Santos-Benito F.F. and Avila J. -LRB- 2000 -RRB-	47990
Cordero M.I. , Santos-Benito F.F. and Avila J.	47990
Cordero M.I.	47990
Santos-Benito F.F.	48004
Avila J.	48027
2000	48037
Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia .	48044
Functional recovery	48044
paraplegic rats and motor axon regeneration	48067
paraplegic rats	48067
motor axon regeneration	48087
their spinal cords	48114
olfactory ensheathing glia	48136
Neuron 25 , 425 - 435 .	48164
Neuron 25	48164
425 - 435	48175
Resnick D.K. , Cechvala C.F. , Yan Y. , Witwer B.P. , Sun D. and Zhang S. -LRB- 2003 -RRB- .	48185
Resnick D.K.	48185
Cechvala C.F. , Yan Y. , Witwer B.P. , Sun D. and Zhang S. -LRB- 2003 -RRB-	48199
Cechvala C.F. , Yan Y. , Witwer B.P. , Sun D. and Zhang S.	48199
Cechvala C.F.	48199
Yan Y.	48214
Witwer B.P.	48222
Sun D.	48235
Zhang S.	48246
2003	48256
Adult olfactory ensheating cell transplantation for acute spinal cord injury .	48263
Adult olfactory ensheating	48263
cell transplantation for acute spinal cord injury	48290
cell transplantation	48290
acute spinal cord injury	48315
J. Neurotrauma 20 , 279-285 .	48341
J.	48341
Neurotrauma 20 , 279-285	48344
Schwab M.E. and Caroni P. -LRB- 2008 -RRB- .	48369
Schwab M.E. and Caroni P.	48369
2008	48396
Antibody against myelin-associated inhibitor of neurite growth	48403
Antibody	48403
myelin-associated inhibitor of neurite growth	48420
myelin-associated inhibitor	48420
neurite growth	48451
nonpermissive substrate properties of CNS white matter	48478
nonpermissive substrate properties	48478
CNS white matter	48516
Neuron 60 , 404-405 .	48534
Neuron 60	48534
404-405	48545
Straley K.S. , Foo C.W. and Heilshorn S.C. -LRB- 2010 -RRB- .	48554
Straley K.S. , Foo C.W. and Heilshorn S.C.	48554
2010	48597
Biomaterial design strategies for the treatment of spinal cord injuries .	48604
Biomaterial design strategies	48604
the treatment	48638
spinal cord injuries	48655
J. Neurotrauma 27 , 1-19 .	48677
J.	48677
Neurotrauma 27 , 1-19	48680
Tatard V.M. , D'Ippolito G. , Diabira S. , Valeyev A. , Hackman J. , McCarthy M. , Bouckenooghe T. , Menei P. , Montero-Menei C.N. and Schiller P.C. -LRB- 2007 -RRB- .	48702
Tatard V.M.	48702
D'Ippolito G. , Diabira S. , Valeyev A. , Hackman J. , McCarthy M. , Bouckenooghe T. , Menei P. , Montero-Menei C.N. and Schiller P.C. -LRB- 2007 -RRB-	48715
D'Ippolito G. , Diabira S. , Valeyev A. , Hackman J. , McCarthy M. , Bouckenooghe T. , Menei P. , Montero-Menei C.N. and Schiller P.C.	48715
D'Ippolito G.	48715
Diabira S.	48730
Valeyev A.	48742
Hackman J.	48754
McCarthy M.	48766
Bouckenooghe T.	48779
Menei P.	48796
Montero-Menei C.N.	48806
Schiller P.C.	48829
2007	48844
Neurotrophin-directed differentiation of human adult marrow stromal cells to dopaminergic-like neurons .	48851
Neurotrophin-directed differentiation	48851
human adult marrow stromal cells	48892
dopaminergic-like neurons	48928
Bone 40 , 360-373 .	48955
Bone 40	48955
360-373	48964
Vaquero J. , Zurita M. , Oya S. and Santos M. -LRB- 2006 -RRB- .	48973
Vaquero J.	48973
Zurita M. , Oya S. and Santos M. -LRB- 2006 -RRB-	48985
Zurita M. , Oya S. and Santos M.	48985
Zurita M.	48985
Oya S.	48996
Santos M.	49007
2006	49018
Cell therapy using bone marrow stromal cells in chronic paraplegic rats : systemic or local administration ?	49025
Cell therapy using bone marrow stromal cells in chronic paraplegic rats	49025
Cell therapy	49025
bone marrow stromal cells in chronic paraplegic rats	49044
bone marrow stromal cells	49044
chronic paraplegic rats	49073
systemic or local administration	49098
systemic	49098
local administration	49110
Neurosci	49132
Lett	49142
398,129-134	49148
Verdu E. , Garcia-Alias G. , Fores J. , Gudiño-Cabrera G. , Muñeton V.C. , Nieto-Sampedro M. and Navarro X. -LRB- 2001 -RRB- .	49161
Verdu E.	49161
Garcia-Alias G. , Fores J. , Gudiño-Cabrera G. , Muñeton V.C. , Nieto-Sampedro M. and Navarro X. -LRB- 2001 -RRB-	49171
Garcia-Alias G. , Fores J. , Gudiño-Cabrera G. , Muñeton V.C. , Nieto-Sampedro M. and Navarro X.	49171
Garcia-Alias G.	49171
Fores J.	49188
Gudiño-Cabrera G.	49198
Muñeton V.C.	49217
Nieto-Sampedro M.	49231
Navarro X.	49253
2001	49265
Effects of ensheating cells	49272
Effects	49272
ensheating cells	49283
photochemically damaged spinal cord	49318
Neuroreport 12 , 2303-2309 .	49355
Neuroreport 12	49355
2303-2309	49371
Verdu E. , Garcia-Alias G. , Fores J. , Lopez-Vales R. and Navarro X. -LRB- 2003 -RRB- .	49382
Verdu E.	49382
Garcia-Alias G. , Fores J. , Lopez-Vales R. and Navarro X. -LRB- 2003 -RRB-	49392
Garcia-Alias G. , Fores J. , Lopez-Vales R. and Navarro X.	49392
Garcia-Alias G.	49392
Fores J.	49409
Lopez-Vales R.	49419
Navarro X.	49438
2003	49450
Olfactory ensheathing cells transplanted in lesioned spinal cord	49457
Olfactory ensheathing cells	49457
lesioned spinal cord	49501
loss of spinal cord parenchyma	49530
loss	49530
spinal cord parenchyma	49538
functional recovery	49573
Glia 42 , 275-286 .	49594
Glia 42	49594
275-286	49603
Wang B. , Zhao Y. , Lin H. , Chen B. , Zhang J. , Zhang J. , Wang X. , Zhao W. and Dai J. -LRB- 2006 -RRB- .	49612
Wang B.	49612
Zhao Y. , Lin H. , Chen B. , Zhang J. , Zhang J. , Wang X. , Zhao W. and Dai J. -LRB- 2006 -RRB-	49621
Zhao Y. , Lin H. , Chen B. , Zhang J. , Zhang J. , Wang X. , Zhao W. and Dai J.	49621
Zhao Y.	49621
Lin H.	49630
Chen B.	49638
Zhang J.	49647
Zhang J.	49657
Wang X.	49667
Zhao W.	49676
Dai J.	49688
2006	49696
Phenotypical analysis of adult rat olfactory ensheathing cells on 3-D collagen scaffolds .	49703
Phenotypical analysis of adult rat	49703
Phenotypical analysis	49703
adult rat	49728
olfactory ensheathing cells on 3-D collagen scaffolds	49738
olfactory ensheathing cells	49738
3-D collagen scaffolds	49769
Neurosci	49793
Lett	49803
401 , 65 - 70 .	49809
401	49809
65 - 70	49814
Wang B. , Han J. , Gao Y. , Xiao Z. , Chen B. , Wang X. , Zhao W. and Dai J. -LRB- 2007 -RRB- .	49822
Wang B.	49822
Han J. , Gao Y. , Xiao Z. , Chen B. , Wang X. , Zhao W. and Dai J. -LRB- 2007 -RRB-	49831
Han J. , Gao Y. , Xiao Z. , Chen B. , Wang X. , Zhao W. and Dai J.	49831
Han J.	49831
Gao Y.	49839
Xiao Z.	49847
Chen B.	49856
Wang X.	49865
Zhao W.	49874
Dai J.	49886
2007	49894
The differentiation of rat adipose-derived stem cells into OEC-like cells on collagen scaffolds by co-culturing with OECs .	49901
The differentiation	49901
rat adipose-derived stem cells	49924
OEC-like cells	49960
collagen scaffolds	49978
OECs	50018
Neurosci	50024
Lett	50034
421 , 191-196 .	50040
421	50040
191-196	50045
Yarak S. and Okamoto O.K. -LRB- 2010 -RRB- .	50054
Yarak S. and Okamoto O.K.	50054
2010	50081
Human adipose-derived stem cells : current challenges and clinical perspectives .	50088
Human adipose-derived stem cells	50088
current challenges and clinical perspectives	50122
current challenges	50122
clinical perspectives	50145
An	50168
Bras .	50172
Dermatol	50178
85 , 647-656 .	50188
85	50188
647-656	50192
Zeltinger J. , Sherwood J.K. , Graham D.A. , Müeller R. and Griffith L.G. -LRB- 2001 -RRB- .	50201
Zeltinger J.	50201
Sherwood J.K. , Graham D.A. , Müeller R. and Griffith L.G. -LRB- 2001 -RRB-	50215
Sherwood J.K. , Graham D.A. , Müeller R. and Griffith L.G.	50215
Sherwood J.K.	50215
Graham D.A.	50230
Müeller R.	50243
Griffith L.G.	50259
2001	50274
Effect of pore size and void fraction on cellular adhesion , proliferation , and matrix deposition .	50281
Effect	50281
pore size and void fraction on cellular adhesion , proliferation , and matrix deposition	50291
pore size and void fraction	50291
cellular adhesion , proliferation , and matrix deposition	50322
Tissue Eng .	50379
Tissue	50379
Eng	50386
7 , 557-572 .	50391
7	50391
557-572	50394
Zhang L. , Ma Z. , Smith G.M. , Wen X. , Pressman Y. , Wood P.M. and Xu X.M. -LRB- 2009 -RRB- .	50403
Zhang L.	50403
Ma Z. , Smith G.M. , Wen X. , Pressman Y. , Wood P.M. and Xu X.M. -LRB- 2009 -RRB-	50413
Ma Z. , Smith G.M. , Wen X. , Pressman Y. , Wood P.M. and Xu X.M.	50413
Ma Z.	50413
Smith G.M.	50420
Wen X.	50432
Pressman Y.	50440
Wood P.M.	50453
Xu X.M.	50467
2009	50476
GDNF-enhanced axonal regeneration and myelination following spinal cord injury	50483
GDNF-enhanced axonal regeneration	50483
myelination following spinal cord injury	50521
myelination	50521
spinal cord injury	50543
primary effects on neurons	50577
primary effects	50577
neurons	50596
Glia 57 , 1178-1191 .	50605
Glia 57	50605
1178-1191	50614
Zuk P.A. , Zhu M. , Mizuno H. , Huang J. , Futrell J.W. , Katz A.J. , Benhaim P. , Lorenz H.P. and Hedrick M.H. -LRB- 2001 -RRB- .	50625
Zuk P.A.	50625
Zhu M. , Mizuno H. , Huang J. , Futrell J.W. , Katz A.J. , Benhaim P. , Lorenz H.P. and Hedrick M.H. -LRB- 2001 -RRB-	50635
Zhu M. , Mizuno H. , Huang J. , Futrell J.W. , Katz A.J. , Benhaim P. , Lorenz H.P. and Hedrick M.H.	50635
Zhu M.	50635
Mizuno H.	50643
Huang J.	50654
Futrell J.W.	50664
Katz A.J.	50678
Benhaim P.	50689
Lorenz H.P.	50701
Hedrick M.H.	50717
2001	50731
Multilineage cells from human adipose tissue : implications for cell-based therapies .	50738
Multilineage cells from human adipose tissue	50738
Multilineage cells	50738
human adipose tissue	50762
implications for cell-based therapies	50784
implications	50784
cell-based therapies	50801
Tissue Eng .	50823
Tissue	50823
Eng	50830
7 , 211-228 .	50835
7	50835
211-228	50838
Zurita M. and Vaquero J. -LRB- 2006 -RRB- .	50847
Zurita M. and Vaquero J.	50847
2006	50873
Bone marrow stromal cells	50880
cure of chronic paraplegic rats : functional and morphological outcome one year	50918
cure of chronic paraplegic rats	50918
cure	50918
chronic paraplegic rats	50926
functional and morphological outcome one year	50951
functional and morphological outcome	50951
one year	50988
transplantation	51003
Neurosci	51020
Lett	51030
402 , 51-56 .	51036
402	51036
51-56	51041
Zurita M. , Vaquero J. , Bonilla C. , Santos M. , De Haro J. , Oya S. and Aguado C. -LRB- 2008 -RRB- .	51048
Zurita M.	51048
Vaquero J. , Bonilla C. , Santos M. , De Haro J. , Oya S. and Aguado C. -LRB- 2008 -RRB-	51059
Vaquero J. , Bonilla C. , Santos M. , De Haro J. , Oya S. and Aguado C.	51059
Vaquero J.	51059
Bonilla C.	51071
Santos M.	51083
De Haro J.	51094
Oya S.	51106
Aguado C.	51117
2008	51128
Functional recovery of chronic paraplegic pigs after autologous transplantation of bone marrow stromal cells .	51135
Functional recovery	51135
chronic paraplegic pigs	51158
autologous transplantation	51188
bone marrow stromal cells	51218
Transplantation 86 , 845-853 .	51245
Transplantation 86	51245
845-853	51265
